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ABSTRACT
Linkage disequilibrium studies have discovered few gene-disease associations for
common diseases. The explanation has been offered that complex modes of inheritance
govern risk for cancers, cardiovascular and cerebrovascular diseases, and diabetes. Such
studies, however, depended on the untested assumption of monoallelic risk. My research
advisor and I set out to investigate whether simple forms of inherited risk, monoallelic or
multiallelic, could be excluded by analysis of familial risk for a common disease, such as
colorectal cancer (CRC). First, we derived formulae that describe the risk for monogenic,
multigenic, and polygenic possibilities of Mendelian inheritance. Next, we obtained an
estimate of minimum lifetime risk for CRC of >0.26. Then, we examined the case of late-
onset CRC, using the Swedish Family Cancer Database (1958-2002) to estimate the
familial relative risk for CRC diagnosis at age 50 or older, and obtained an estimated
range of 1.5 to 3.0. We compared this range of actual values to the ranges of expected
values for monogenic, multigenic, and polygenic modes of inheritance. We delimited
bounds that can be placed on the conditions for various modes of inheritance. The key
observation is that monogenic risk for CRC is included among various possibilities, and
cannot be eliminated by existing observations. The arguments herein indicate that further
efforts can and should be made to obtain more precise estimates of familial risk for CRC
and other common forms of cancer.
Thesis Supervisor: William G. Thilly
Title: Professor of Toxicology
'Development of Western science is based on two great achievements: the invention of
the formal logical system (in Euclidean geometry) by the Greek philosophers, and the
discovery of the possibility to find out causal relationships by systematic experiment
(during the Renaissance).'
Albert Einstein (1953)
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INTRODUCTION
Rates of most common forms of cancer rose in urbanizing societies in the early- to mid-
twentieth century, while gastric cancer rates declined (http://epidemiology.mit.edu). With
the exception of the role of cigarette use in lung cancer, the environmental changes
responsible for these changes in cancer rates are unknown. For each form of cancer, it has
been postulated that the changing environmental conditions interacted with one or more
mutant forms of unknown genes to change the rate of oncogenic mutations, the rate of
growth of preneoplastic lesions, or both (Herrero-Jimenez, Thilly et al. 1998; Herrero-
Jimenez, Tomita-Mitchell et al. 2000). In addition to environmental exposure and genetic
susceptibility, it is also possible that individual risk is dependent on stochastic factors,
which may themselves be functions of genetics and/or environment. For example, if
tumor initiation mutations were limited to the juvenile period, otherwise susceptible
persons reaching adulthood without an initiated stem cell would be without subsequent
risk by chance (Gostjeva and Thilly 2005). Family studies have clearly established a
familial risk for most common forms of cancer (Lichtenstein, Holm et al. 2000; Czene,
Lichtenstein et al. 2002). These observations serve as the basis for the hypothesis that
there are genes that carry mutant alleles conferring lifetime risk, subject to environmental
exposure and stochastic events. Most of the -2000 recognized rare inherited syndromes
have been accounted as a multi-allelic set of mutations in a single gene (monogenic risk)
while a few rare syndromes have been shown to arise from multi-allelic sets of mutations
in any of two or more genes (multigenic and/or polygenic risk) (http://www.hgmd.org).
To date, only two genes have been convincingly associated with common diseases, the
melanocortin I receptor gene, MCIR, with skin cancers (Rees 2000; Rees 2004), and the
complement factor H gene, HFIICFH with macular degeneration (Hageman, Anderson et
al. 2005). (The term "common diseases" as used in this thesis refers to diseases that may
afflict -1% or more of the population during a lifetime, and includes vascular diseases,
cancers, diabetes, and late-onset conditions broadly associated with aging.)
In the current research, we are exploring the intersection of estimates of lifetime risk and
familial risk for common forms of cancer in an attempt to delimit the kinds of genetic risk
that may govern familial risk. We seek to discover if there is any reason to assume that
such risks involve one or many genes, and whether or not these risks exclude ordinary
modes of Mendelian inheritance in which heterozygosity or nulizygosity for one or more
genes define risk. In this collaborative effort, Prof. K. Hemminki is kindly providing data
from the Swedish Family Cancer Database (1958-2002), that permit independent
calculation of the minimum fraction of persons at risk both in the general population and
in the subpopulation with a family history of common cancers. As an example of a
common cancer, we use colorectal cancer throughout this thesis, but derive simple
algebraic models applicable to all forms of cancers or other common diseases. We have
derived formulae that describe the expectation of inherited risk from monogenic,
multigenic, and polygenic possibilities for the several Mendelian possibilities. These
formulae have made it possible to compare theoretical expectations with actual data
drawn from a large human population (Sweden, 1958-2002) to discover if any class or
classes of simple forms of inheritance are arithmetically excluded. To carry out this
objective, it was necessary to revise existing practices in calculations of age-specific
familial relative risk to make them applicable to the quantitative estimation of the relative
risk conveyed by inheritance. The revision involved broad reconsideration of the
processes of carcinogenesis, to account for established facts, and to maintain a parallel
relationship between mathematical and physiological models. Our results applied to
colorectal cancer demonstrate that not all monogenic forms of risk are eliminated by the
intersection of data on lifetime age-specific risk, familial risk and the quantitative
distribution of gene-inactivating mutations in the human population.
The results of these analyses are already being applied to the design of experiments to
discover the genes conferring risk for common forms of disease including all common
forms of cancer. Researchers planning pan-genomic searches, such as Prof. G.M. Church
of Harvard University, Prof. R.W. Davis of Stanford University, and my research advisor,
can proceed with the expectation that while, as in the case of MCIR and skin cancers,
genetic risk for other common cancers may in fact be conferred by mutations in a single
gene, search strategies must comprehend the possibility of multi- and polygenic risks.
BACKGROUND
Goal and Motivation
This thesis intends to contribute to our understanding of inherited risk for late-onset
forms of common cancers, which constitute more than 95% of all cancer deaths. In
particular, we seek to discover if the simplest monogenic forms of Mendelian inheritance
are excluded by any combination of data and/or logic. Motivation has been given by the
failure of the extensive effort to use linkage disequilibrium mapping methods applied in
the general population to discover any gene that carries risk for any common cancer.
Search for genes carrying mutations conferring inherited risk for common diseases
Public apologia for the method of linkage disequilibrium has hypothesized that inherited
risk must be conferred independently by multiple genes, each gene carrying but a single
risk-conferring mutation in the general population. This is a scenario of mono-allelic,
multigenic risk. This idea seeks to explain the failure to discover gene-common diseases
association by presenting a scenario in which the "true" bases for inherited risk for
common diseases are essentially too complex for discovery using linkage disequilibrium
studies in genetically heterogeneous populations. In practical terms, multigenicity has the
effect of reducing the fraction of an affected cohort carrying risk from each particular
contributing gene studied. The idea seems to be that if there were simple conditions of
monogenic risk with Mendelian inheritance, linkage disequilibrium studies would have
found them.
This failure has, however, been more formally addressed in terms of a direct
contradiction of the central hypothesis underlying linkage disequilibrium methods: they
depended on the arguments of Kimura and Crow (1964) for mono-allelic, as well as
monogenic risk for common diseases (Lander and Botstein 1989; Lander and Schork
1994; Tomita-Mitchell, Muniappan et al. 1998; Morgenthaler and Thilly 2006).
In Morgenthaler and Thilly (2006), the many known examples of generative mutational
spectra encoding risk for rare inherited diseases in humans, the age and population size of
the species H. sapiens were presented as a basis for the expectation that inherited risk for
common diseases would be expected to be markedly multiallelic, absent selection of any
particular mutant allele. But Morgenthaler and Thilly accepted the possibility that
inherited risks were conferred by a single gene (monogenic risk) or multiple genes
(multigenic and/or polygenic risk). They offered a combination of statistical logic and
technical advances to discover gene-disease association via pangenomic pair wise trials
that they argued would detect most, if not all, associations independently of the mono- or
multi-allelic, mono-, multi-, or poly-genic nature of the inherited risk(s).
While Morgenthaler and Thilly (2006) accepted the need to design an analytical strategy
that would capture both monogenic and multigenic risks in genetically heterogeneous
populations, we questioned the assumption that genetic risks were perforce multigenic
and/or polygenic, i.e. complex. What data supported such a contention? Were there any
specific data that excluded simple monogenicity? If we could provide answers to these
questions our effort could be used in planning the search for genes associated with any
and all common diseases. If risks were monogenic then enumeration of the point
mutations in the exonic sequences of a test gene in a case-control study with cohorts as
small as 1,000 persons could discover the gene in a pan-genomic scan enumerating all
point mutations in the exonic sequences of all genes; if monogenic risks were excluded
then case cohorts of 10,000 or even larger would be required (Morgenthaler and Thilly
2006).
This is not a minor point. Public skepticism expressed in reduced support for public
health research by the U.S. Congress is in part due to the failure of the promised genomic
revolution to discover gene-common disease associations, an effort that has consumed an
estimated fifteen billion dollars of public and private investment in the past decade
without tangible results. The estimated cost of pan-genomic studies of -100 common
diseases has been estimated at -$250 billion using the most recent high throughput
strategies if 10,000 persons are required in case cohorts. But various elements of the
National Genome Institute are proceeding on the assumption that only a modest subset of
known genes need be screened in case cohorts of -~ 1,000 persons, a strategy dependent on
a dependable means to identify genes conferring risk (which does not exist) and a
condition of monogenic or near monogenic risk for each disease studied (Morgenthaler
and Thilly 2006). The predictable failure of these efforts will further erode public
confidence in population genetics and science in general. It is necessary to analyze the
data regarding risk of common cancers and other common diseases in order to create and
execute a plan that will discover such genes that carry inherited risks. Science and society
cannot really afford a continuing obfuscation of the truth about genetic risks.
Insofar as there are rare inherited syndromes that are monogenic and multi-allelic, such as
phenylketonuria and cystic fibrosis, or multigenic and multi-allelic, such as the
recessively inherited xeroderma pigmentosum (XP), where any of 7 nucleotide excision
repair genes are involved (XPA-XPG), the dominantly inherited hereditary non-polyposis
colorectal cancer (HNPCC, Lynch syndrome), where any of 5 mismatch repair genes are
implicated (MLH1, MSH2, MSH6, PMS2, PMSI), and others, there is no reason to
assume that risk for any particular common disease must be either monogenic or
multigenic. Indeed, the medical classification of diseases must often be expected to group
conditions of differing genetic etiology with common, if not explicitly identical, sets of
symptoms. This being recognized, we set out to gather, organize, and analyze the existing
forms of epidemiological and clinical data to discover if there were any bases for
excluding the hypothesis of monogenic risk. We began with a new model of the
quantitative distribution of gene-inactivating mutations among genes within the general
human population (Morgenthaler and Thilly 2006).
The distribution of gene inactivating mutations in the human population
(Abstracted and edited from Morgenthaler and Thilly (2006), with permission)
As we are concerned with detecting perhaps one to many genes carrying risk-conferring
mutations per common disease, it is important at the outset to have some concept of the
expected number of both gene-inactivating and neutral gene-inactivating mutations/gene
exonic segments, and their distributions over all genes. These expected numbers and their
distributions have not yet been satisfactorily determined by observation. Here are
employed: (i) observations of some 135 gene-inactivating mutation rates, (ii) an estimate
of the age of the human species, and (iii) the relative numbers of gene-inactivating and
neutral mutations distributed in the human genome's exons. The confluence of these data
permits an initial estimate of the mean frequency and distribution of non-deleterious but
gene-inactivating mutations in humans.
The mean rate of inherited gene-inactivating mutations in humans has been estimated on
the basis of 135 gene "loci" for deleterious mutations to be about (3 ± 0.7) x 10-6 (± S.E.
of the mean) per generation (Sankaranarayanan and Chakraborty 2000).
One might thus expect that accumulation of non-deleterious gene inactivating mutations
summing per gene to an average approaching 0.03 has occurred during the -250,000
years or -10,000 generations estimated for the age of H. sapiens (McDougall, Brown et
al. 2005).
To these must be added such high frequency non-deleterious polymorphisms in a small
fraction of genes that were carried forward from the earlier hominid population or arising
in the aboriginal human population. Among the single locus estimate, a range of mutation
rates of I x 10-6 to 22 x 10-6 was also noted. Insofar as the upper limit of 22 x 10-6
inactivating mutations/generation was observed in 135 "trials", we may use a "Fermi
approximation" to posit that - 1% of genes carrying non-deleterious gene inactivating
mutations would carry an inactivated gene copy fraction at a level of about 0.22. Summed
gene-inactivating allele frequencies for some genes, such as 0.3 for cytochrome P450
2D6 or 0.8 for glutathione methyl-transferases, demonstrate that frequencies exist above
this roughly approximated 99% upper confidence limit (Strange and Fryer 1999;
Cascorbi 2003).
Genes carrying recessive deleterious mutations also require consideration insofar as
heterozygosity may confer risk for a common disease. In Hardy-Weinberg equilibrium,
the steady state fraction of gene copies carrying deleterious mutations is approximately
equal to the square root of the forward mutation rate, or about 1.7 x 10-3, which would
result in an average heterozygote fraction of 2pq-3.4 x 10-3 in the general population,
where q is the fraction of gene copies carrying gene-inactivating, risk-conferring
mutations and p = J-q. Were three such genes' conditions of heterozygosity to confer risk
for the same disease, a common, multigenic, - 1% risk would be achieved. Given an
approximation of 22 x 10-6 as of the 99% upper confidence limit on forward mutation
rates, one would expect a heterozygote fraction of - 9.3 x 10-3 in the general population,
so that some recessive deleterious conditions may be expected to create risk for less
common "common " diseases. Absent more precise knowledge of the architecture of
human population genetics, a prudent technical strategy would comprehend potentially
important risk-conferring mutant fractions, i.e. gene-inactivating, to values of q between
10-3 and 1.0. Based on experimental measurements by Sankaranarayanan and
Chakraborty (2000) of inactivating mutations per gene copy, the mean and upper
confidence limits have been estimated as follows:
Gene-inactivating mutations/gene's exonic segments:
Mean - 0.03 ± 0.081 (SD)
90% u.c.l. - 0.03 + 1.28 x 0.081 = 0.134
99% u.c.l. - 0.03 + 2.33 x 0.081 = 0.22
Estimates of' neutral mutation frequencies have also been made based on the expectations
of gene-inactivating mutations and recognition that the ratio of gene-inactivating to total
exonic point mutations is approximately 12 in humans (derived from analyses of the SNP
Database by Dr. B.J. Glassner, as reported in Morgenthaler and Thilly, 2006)
Neutral mutations/gene's exonic segments:
Mean - 0.33 ± 0.894 (SD)
90% u.c.l. - 0.33 + 1.28 x 0.894 = 1.48
99% u.c.l. - 0.33 + 2.33 x 0.894 = 2.41
Scanning of five genes, HBB, POLB, CTLA4, PPARyand TPMT, by Prof. W.G.Thilly
and his collaborators provide some assurance, based on comparisons to the estimates of
neutral mutation frequencies, that the estimates of dispersion for gene-inactivating mutant
fractions, q, are reasonably precise. Though five genes is too small a sample to use to
describe the mean and distribution for all genes, scans of the exons of these genes found a
range of total mutations/gene's exonic segments to be 0.1 to 0.8 with a mean of about 0.4
in reasonable accordance with the calculated estimates of 0.33 + 0.03 = 0.36 with a 90%
u.c.l. of -~ 1.5 cited above. These uncertainties must be accepted pro tempore. Here, we
employ these rough approximations to consider the conditions of monogenicity,
multigenicity and polygenicity that are consistent with inherited risk for common
diseases, such as colorectal cancer.
Large population databases with age-specific cancer rates
There were essentially two major sets of epidemiological data to explore. The first
comprises the national historical records of age-specific mortality rates from common
diseases, including many common forms of cancer. For instance, in the United States
such records have been kept in a way that they can be matched to age-specific population
numbers since 1900. Similar data have been recorded in Japan since 1952. These are
available via http://epidemiology.mit.edu. Many other countries have maintained cancer
registries; Sweden began its national cancer registry in 1958. Analyses of these data
permit inferences about the history of changes in environmental risk for particular
diseases. They also provide a means to calculate a minimum estimate of the fraction at
genetic risk of a particular disease.
These age-specific national data sets do not, however, permit an explicit calculation of
the relative risk that affects the first-degree relatives of an individual with a particular
disease. Each first-degree relative would, in general, carry half of the mutant autosomal
genes of the afflicted individual. Currently, the largest available data set for analyses of
inherited risk for common diseases is the Swedish Family Cancer Database created and
maintained by the research group of Prof. K. Hemminki, formerly at the Karolinska
Institute, Huddinge, Sweden, and now at the Deutches Krebsforschungszentrum (DKFZ),
Heidelberg, Germany (Hemminki, Li et al. 2001; Hemminki, Granstrom et al. 2005).
Another database, which has yielded valuable results, and includes fewer individuals, but
more generations, is the Utah Population Database (Goldgar, Easton et al. 1994).
Concept of an age-specific familial relative risk of a common disease, FRR(t)
In developing my arguments we used examples from the Swedish Family Cancer
Database to consider the age-specific cancer rates in the general population and in the
subpopulations of children with at least one parent with a late-onset cancer and of parents
of at least one child with a late onset cancer. We have chosen the incidence of colorectal
cancers (CRC) in Sweden and the U.S. to illustrate the value and limitations of our
results. Using a general "two-stage" model of carcinogenesis, we argue that the ratios of
age-specific risk early in the earlier late-onset cancer age intervals (ages 50-54,...,70-74),
FRR (t; late-onset), between the subpopulations with a parent or child diagnosed with a
late onset cancer to the age-specific risk in the general population of parents or children
approximates the Genetic Relative Risk, GRR. We chose these age intervals because
early-onset forms of CRC, such as FAP and HNPCC syndromes, have already had their
effects by this age, and the fraction of persons at risk of late-onset CRC has not yet been
significantly diminished by CRC mortality.
Heretofore, the familial relative risk was calculated either on the basis of two or more
cancers within a parent-child relationship, without regard to age or gender, or by
grouping all familial concordant cases, wherein both afflicted persons were of age 50 or
greater.
Grouping by age and gender are, however, logical requirements in the definition of
familial genetic risk. For late-onset colorectal cancer in persons between 50 and 74, the
estimated familial relative risk is about 1.89 (Hemminki and Chen 2004). Nonetheless,
about 40% of the cases of CRC among "children" born since 1932 were recorded at age
0-49, and a significant number of parent/child concordant cases actually involved a late-
onset diagnosis in a parent and an early-onset case in a child, leading to the expectation
that the value 1.89 is an underestimate of the value of familial relative risk for late-onset
CRC. In contrast, the use of data clustered over all ages of late-onset disease as in the use
of an age-interval 50-104, automatically leads to an overestimate of the value of genetic
risk, because the values of FRR(t; late-onset) must increase significantly with age.
With regard to gender, for most cancer sites, with the exception of gallbladder cancer and
thyroid cancer (in particular, papillary thyroid cancer), age-specific incidence or mortality
rates are greater in males than females. Thus, genetic risk for cancer in a father or mother
would have a higher probability of being observed in a son than in a daughter. The
probability of observing genetic transmission from afflicted parents would be expected to
be greater for sons than for daughters. Calculations based on pooled gender data would
be expected to create a bias leading to underestimates of GRR.
The formal algebra underlying these general points is derived below in the section
Familial Relative Risk.
As this thesis is being written, recognition of limitations of these two forms of expressing
familial relative risk in estimating genetic risk is having a positive effect. Data from the
Swedish Family Cancer Database are being re-organized to permit calculation of FRR(t)
for common late-onset cancers using our specific re-definition of FRR(t), and to account
for gender.
For our purposes herein, we use a broad preliminary estimate of FRR between 1.5 and 3.0
for CRC in Sweden.
Based on observations of unchanging CRC rates in birth cohorts of the 20th-century in
Sweden and the U.S.A., and demonstration of the absence of any spousal risk for CRC in
Sweden (Hemminki, Dong et al. 2001; Hemminki and Jiang 2002), we further argue that
FRR (t = 50-54,...,70-74) for male to male transmission for the birth decades of 1900-
1909 and onward, represents the genetic relative risk (GRR), for late-onset cancers.
Then, we formally consider a wide set of modes of Mendelian inheritance and calculate
their expected GRR values over a wide range of fractions at genetic risk in the general
population.
Formal expressions for genetic relative risk, for autosomal and sex-linked monogenic
disorders, were previously derived for various kinds of relatives, using stochastic
matrices (Li and Sacks 1954). Another method to obtain such expressions is using path
analysis. Yet another approach is via mating tables, where parental and offspring
combinations are numerated, probabilities are calculated, and values are summated. The
latter approach allows a more tractable extension to multigenic and polygenic modes of
inheritance, and was the method followed. We have confirmed the calculations of Li and
Sacks for monogenic risks, and have extended them as the first algebraic derivation for
expected values of GRR for multigenic and polygenic conditions of inherited risk.
One point should be emphasized: the data of the Swedish Family Cancer Database,
organized by the Hemminki group, clearly demonstrate that there is a familial risk for
common late-onset cancers. The derivation of algebra to use these data to obtain a more
accurate estimate of GRR builds on this accomplishment, and seeks to use it to delimit the
possible modes of risk inheritance.
Using these derived algebraic formulae, we have created and provided tables herein by
which researchers may use the estimate of the minimum lifetime risk, mLR, for any
common disease, the estimates of GRR as derived from values of FRR(t) in the earlier
years of late-onset diseases, and the observed mean and 99% upper confidence levels
(u.c.l.) of q for gene inactivating allelic fractions in humans (Morgenthaler and Thilly
2006), to discover if any hypothesized form of monogenic, simple multigenic or simple
polygenic risk are excluded by this set of disparate observations.
For illustrative purposes, we use the present rough estimates of GRR for CRC in Sweden,
the minimum lifetime risk, mLR, for CRC in Sweden and the U.S., and an estimate of the
range of values of q for inactivated gene copies in the human population. We apply this
to the case of CRC risk. The value of our derivations and logic will increase as better
estimates of these three parameters, particularly GRR, accrue.
Common cancers: a historical overview
Before launching into the specifics of our effort, we owe our readers an overview of the
cancer problem that underlies our effort. As this thesis is written, the field of cancer
research has received many powerful analytical tools and opportunities from the
disciplines of statistics, epidemiology, population genetics, somatic genetics, histology,
cytology, toxicology, molecular biology and biochemistry.
Unfortunately, these advances have not yet reduced age-specific mortality rates from the
set of all-too-common late-onset cancers. Many improvements are observable for specific
cancer types, however: the effect of fluorouracil therapy on skin cancers, Gleevec on
chronic myelogenous leukemia, decreased cigarette use on lung cancer, and the
unexplained historical decrease in gastric cancer. Insofar as a statistically significant
decrease in overall reported cancer mortality rates in the U.S.A. since 1960 parallels the
nationwide decrease in autopsies, some skepticism as to the validity of the conclusion
that cancer rates are dropping is justified. The historical record of deaths from all
malignancies in U.S. European American Males (EAM) and Females (EAF) (Figure la,
b.) appears to indicate that by the birth cohorts of the late 19 th- and early 20t-century, a
new but relatively constant age-specific rate of cancer mortality had been established in
these ethnic- and gender-specific cohorts. Whereas women born in the early 19th-century
had somewhat higher age-specific cancer mortality rates than men, increases in rates
among males rose above the female rates in a historical process that can be seen in
successive birth decades beginning with that of the 1820s.
However, plotting the age-specific mortality data, 1900-1997, for EAM for the birth
cohorts from 1890-1899 to 1970-1979 (Figure 2) betrays no discernible differences
among birth decade cohorts. While there are some increases and decreases in age-
specific mortality rates in different sites for European Americans born during the 2 0 th
century, such as cervical cancer (Pap Test), lung (smoking cessation), and non-melanoma
skin cancers (fluorouracil), these can be accounted by the effects of medical and public
health progress. However important this progress has been for particular cancer types, it
cannot be gainsaid that there is no evidence to support the contentions of the American
Cancer Society and the National Cancer Institute that age-specific cancer mortality rates
have significantly decreased over the past few decades. Indeed, the 1972 "War on
Cancer" was announced at a time when the U.S. autopsy rates were already in a decade-
long decline that continues to this day, a medical-economical phenomenon that would
lead one to expect a growing underestimation of death rates from cancers without
external diagnostic features.
Estimation of the minimum fraction at lifetime risk, mLR
These macro-epidemiological points having been made, it may also be seen that changes
principally increasing overall male cancer mortality rates in the latter half of the 19th- and
early 20th-century (e.g. cigarette use) were well established as risk factors by the birth
cohorts of 1890-1899, 1900-1909, as shown in Figure 2. Inspection of the data of Figure
2 and for nearly all common forms of cancer, save a few, such as leukemias and
lymphomas, shows a maximum value at age intervals ranging from 80-84 to 95-99
depending on cancer type. Given the demonstration by the Hemminki group of a
significant degree of familial risk for common forms of cancer, Herrero-Jimenez et al.
(1998, 2000) devised cancer models to account for these maxima in terms of a specific
population sub-fraction at lifetime risk with a mortality rate perforce greater than in the
sub-fraction not at risk. Applying this reasoning, the area under the lifetime age-specific
incidence curves or mortality curves adjusted for survival through medical intervention,
represented the minimum average number of conditions of cancers carried/experienced
by members of the population. For instance, using the birth decade cohort of 1890-1899
depicted in Figure 2, one may note that the area under the curve is somewhat greater than
1.3. Correcting for survival rates across all cancers of about - 15% this number would
increase to about 1.5. If such risks were Poisson distributed over the entire population
some e-1.5 or -~ 0.22 of the population would not be at lifetime risk of any late-onset
cancer while -0.78 of the population would be at risk of one or more forms of cancer.
One major possibility that overshadows this area of research is that atherosclerosis,
responsible for perhaps half of all late-onset deaths, has common risk factors with some
common forms of cancer. Atherogenesis and carcinogenesis share some important
physiological features, among which are that an atherosclerotic plaque originates as "fatty
streaks" in the juvenile period, is apparently derived from a single precursor cell (clonal),
and creates a log-linear increase in mortality from cardiovascular disease, having the
same approximate slope as most late-onset cancers, -0. 11 (W.G. Thilly, unpublished
observation).
Thus, we carry the idea that overall risk of cancers are distributed over at least 80% of the
population and individuals within the group at risk of any cancer may carry independent
risk(s) for one more cancers. Now, we will use more specific information about CRC to
apply these general logical points to a particular category of cancer diagnoses.
Figure 3 presents the historical record of lower digestive tract age-specific cancer
mortality, which is constituted to some 95% by colorectal cancer. This approximation is
necessary as the data in this form have been recorded since 1900 in the United States,
whereas the specific designations colon cancer and rectal cancers were introduced more
recently in the public record. As in the set of all cancers, CRC mortality for women was
greater than that for men in the birth cohorts of the 19th-century, but male age-specific
rates were greater than female rates by the 20th-century.
Using the data of Figure 4 for the birth decade of 1890-99 for European American males,
it is possible to make an initial calculation of the area under the curve, as a preliminary
estimate of the fraction of this cohort at lifetime risk of death by CRC. This works out to
-0.18. However, improvements in early detection and treatment of CRC during the 2 0 th -
century acted on this cohort as it grew older, especially after 1950 when the cohort
entered its 60s. Herrero-Jimenez organized the medical literature reports of CRC survival
rates as a function of historical year and age so that an age-specific correction could be
applied to the data of Figure 4.
Accounting for improved medical efficacy in early detection and treatment of CRC as
illustrated in Figure 5 yields a better approximation to CRC incidence as a function of
age in the 1890-99 EAM birth cohort. As there were significant improvements in CRC
detection and treatment during the lifespan of this cohort, one is not surprised to note that
the area under the curve has increased to about 0.28. Note that these calculations have
been made for males based only on the assumption that males and females have the same
inherited risks, but that physiological differences, such as number of cells at risk of
initiation, lead to lower lifetime risks in females than males. Thus, our estimates of mLR
are based on male data alone.
Figure 6 depicts the data forwarded by Prof. K.Hemminki for incidence of CRC in male
parents by first-time diagnosis in Swedish hospitals. In this case, the estimate of the area
under the curve needs no correction for survival, and leads to an estimated minimum
fraction of males at lifetime CRC risk of -0.26. The rough estimates of minimum
lifetime risk of CRC in U.S. males (0.28) and Swedish male parents (0.26) are
remarkably similar, and as we will use estimates of familial risk from the Swedish
population, we will adopt pro tempore the value of 0.26 as the minimum estimate of the
Swedish population at lifetime risk of CRC.
Another set of data that may be used to try to estimate the lifetime fraction at risk of
colorectal cancer in European males is the study of the fraction of males in the United
Kingdom with one or more adenomatous polyps in a study organized by Dr. W. Atkin of
St. Mark's Hospital, London (Atkin, Rogers et al. 2004). Among males, this study found
an average of 15% of males over 50 with one or more adenomatous polyps or a more
advanced stage of CRC. The average number of adenomatous polyps among males with
polyps was 1.3. Were said polyps Poisson-distributed among persons at risk of polyp
development and presumably at risk of CRC, then by the formula 1.3 = X/(1- e-), one
may estimate the average number of polyps among persons at risk as X-~0.55. This
permits conversion of the fraction with polyps, 0.15, into an estimate of the fraction at
risk of polyp development of 0.15/(1- e- ) - 0.35. The author opined that the fraction
with polyps may be actually larger than 0.15, with a bias due to lack of experience or
expertise among proctologists.
From these three examples we see that a minimum value of CRC lifetime risk of 0.26
(Sweden) and 0.28 (U.S.) is smaller than the estimate of 0.35 based on serial proctoscopic
examinations in the United Kingdom. This latter fraction might be considered an estimate
of actual lifetime risk, insofar as it comprised observations in men under 65, when
competing forms of death would not interfere with observations. Because of the smaller
population scanned in the Atkin study, there is a greater uncertainty as to the derived
estimate of mLR. We must be satisfied to consider the mLR in European males for CRC
as greater than 0.26 and therefore a minimum estimate of GRR is also about 0.26. As the
mLR estimate is an intersection of genetic, environmental and stochastic risks, these data
do not define an upper limit for GRR.
Confounding variables affecting the estimate of lifetime risk; pleiotropic risk
Interference, with other forms of death with risk factors unrelated to those of CRC would
not interfere with the estimate of minimum lifetime risk in the Swedish and U.S. datasets
as they are comprised of the conditional probabilities of detection or death by CRC, given
that an individual is still alive. However, another possibility to be accounted is that the
same genetic risks may underlie several different forms of cancers, i.e. mutations in one
gene might confer risk for cancers in different tissues, a condition of pleiotropic risk. This
is known for breast and ovarian cancers, and suspected for several other combinations, as
revealed by the Hemminki group's efforts to identify familial cross-sensitivity. Cure or
avoidance of one form of such a set of cancers would in such cases be expected to be
accompanied by increases in the related forms with common genetic etiologies. The
presence of such conditions would cause the area under the incidence curve to be an
underestimate of the lifetime. This confounding possibility is algebraically addressed by
Herrero-Jimenez et al. (1998, 2000), and is formally addressed in the section Cancer
Models.
Environmental risk
We argue that the lifetime risks for late-onset cancers must be functions of environmental
and genetic risk factors acting independently or in concert. We further argue that
inherited risk factors could not have changed to any significant degree in the U.S.
population in the latter part of the 19th-century, because the wave of immigration
consisted mainly of European origins genetically similar to the earlier European
immigrants. Actual gonadal rates of genetic change of - 3 x 10-6 gene inactivations per
generation would be glacial in comparison to the observed rate of changes in lifetime risk
(Sankaranarayanan and Chakraborty 2000).
If genetic risk factors did not change, then all changes in lifetime cancer risk in the birth
decade cohorts of the latter 19th-century must be ascribed to known or unknown
environmental factors. It is prudent, however, to maintain some skepticism that under-
diagnosis and under-reporting in the early 20th-century may have exaggerated the
apparent magnitude of the historical increases in some cases.
Key to the approach that we take in this thesis is the premise based on the data of Figures
1 and 2 that whatever the set of environmental risk factors may have been for any or all
mortal cancers, the condition of environmental risk was established at a historical period
that comprehended the birth decade cohorts of and subsequent to 1900-1909 and that the
fraction(s) of the population at lifetime environmental risk(s) has not changed
significantly for persons in the U.S. born since 1900.
Relevant to these arguments are the data of the Swedish Family Cancer Database,
organized and analyzed by the Hemminki group over the past decade. As in the U.S.A.,
their data recorded for persons born since 1932 and diagnosed with a malignant neoplasia
since 1958, demonstrates no change in age-specific incidence in the birth decade cohorts
beginning with 1930-1939 through the present day. These observations apply to the
twenty most common forms of adult cancers, as well as the sum of all cancers. Some
cancer data recorded in Sweden after 1958 for the oldest Swedes indicates that a rise in
cancer rates occurred in birth decade cohorts of the late 19t-century similar to that
observed in the U.S.A. (Figure 1), but the data are not sufficient to permit more than this
general conclusion. What is important about the findings, such as the data of Figure 2 for
the U.S.A. and Sweden, is that the age-specific cancer rates are essentially unchanged for
the birth decades after 1900-1909; this permits us to consider risks of cancers in the 20th-
century birth cohorts as being constant with regard to environmental risk. Thus, one may
regard the Swedish cohorts of "parents" and "children" as having experienced essentially
identical conditions of environmental risk.
Epidemiologic studies have sought but not found evidence of spousal risk for colorectal
cancer (Hemminki, Dong et al. 2001; Hemminki and Jiang 2002). Shared environment in
adulthood does not appear to play a role in differential risk for most cancers, including
colorectal cancer. A comparison of CRC mortality rates among American communities
(1958-1997), whether urban or rural, by J.A.Vatland (Analysis of community cancer
mortality rates, MIT Ph.D. Thesis, 2001) did not find differences significantly greater
than those expected by chance alone. See Figure 7 for the case of colon cancer mortality
among 520 communities in the U.S. Commonwealth of Pennsylvania.
The importance of this logical point requires emphasis. It means that we may reasonably
consider familial risks to arise solely from genetic risk for the birth year cohorts of the
20th-century. It is tempting to imagine that the homogeneity of cancer risks among
communities discovered by J.A. Vatland in the latter decades of the 20th-century in
America indlicates a saturation of the population with the unknown environmental risk
factors with all or nearly all of the population at uniform environmental risk (E uniform,
though of unknown value), and that all persons now experience unknown uniform kinds
of environmental risk. But this assumption is not necessary for unambiguous
determination of the degree of familial risk for common cancers, using data from the
Swedish Family Cancer Registry as formally derived below in the section FRR(t).
Development of Mathematical Models of the Physiological Processes of
Carcinogenesis
Our next line of logical construction arises from the fifty year-old process of creating
mathematical models for the deterministic and stochastic processes hypothesized to
underlie carcinogenesis in humans. In general, such models are based on the "two-stage"
model first put forth by Armitage and Doll (1957), in which the first stage, "initiation",
consisted of "n" mutations required to change a phenotypically normal cell "cell at risk"
into a cell that could give rise to a slowly growing preneoplastic colony, in which a
preneoplastic "cell at risk" could over time accumulate "m" mutations that would
transform a preneoplastic cell at risk into a neoplastic cell, that would give rise to a
rapidly growing tumor that untreated, kills within a few years of neoplastic
transformation. In this model "progression", the events that occur during growth of the
tumor, may accelerate tumor growth and death but as they inexorably occur within a
short period of years and are essentially ignored.
While a number of mathematical models have attempted to build on Armitage and Doll
(1957), two in particular influenced the present mode of analysis.
The first is that of Stein and Stein (1990) and Stein (1991), in which it was noted that the
apparent constant slope of the log-linear plot of most late-onset cancer mortality data had
a constant value of - 0.11. The second is that of Herrero-Jimenez et al. (1998, 2000), in
which this constant exponential increase was ascribed to a constant growth rate of
preneoplastic colonies, which was recognized as being approximately equal to the growth
rate of human juveniles from 18 months to maturity. In Gostjeva and Thilly (2005), the
argument was extended to note that the expected growth rate of epithelial sheets in
juvenile organs was - 0.11, the same rate noted by the Steins as the slope of the age-
specific increase in cancer mortality rates.
Herrero-Jimenez et al. (1998, 2000) attempted to apply linear approximations to derive
estimates of initiation and promotion rates that were arguably functions of mutation rates,
as well as to estimate the growth rate of preneoplastic colonies, such as adenomatous
colonic polyps. In this effort they misled themselves into believing a true computational
minimum had been discovered, and their specific estimates of initiation and promotion
mutation rates and population risk parameters in CRC are now seen as but one set of
estimates of many possible sets (Gostjeva and Thilly 2005). However, this effort
introduced the only extant treatment of populations as containing persons of differing
genetic risk, and also the first model to account for the possibility that different forms of
cancer shared common environmental and or genetic risk factors.
Other cancer model variants have been offered, such as those of Luebeck and
Moolgavkar (2002), Michor et al. (2004) in the Nowak group, and Frank (2004). These
efforts have, however, explicitly or implicitly assumed that all members of the population
are at risk (Luebeck and Moolgavkar 2002), or attempted to model the hypothesis that
oncogenic mutation rates accelerate during growth of preneoplastic colonies. Insofar as
the studies of the Hemminki group and others with smaller population sizes have
established a clear demonstration that familial cancer risks exist for common forms of
cancers and the obvious division of lung cancer risk among persons who do or do not
smoke cigarettes, we reject the modeling approaches, which, inexplicably to me, assume
that all individuals are at equal cancer risk. With regard to modeling to explain the level
of loss of heterozygosity and point mutations in tumors, these matters seem to me best
remanded to the time in which direct measurements in human tissues will permit
distinguishing between hypotheses that assume serial mutator mutations (Beckman and
Loeb 2006) or a continuation of a hypothesized juvenile mutator phenotype throughout
preneoplasia (Gostjeva and Thilly 2005).
With regard to the many phenomena that might pertain to the effects of unknown or
known environmental risk factors they are beyond the scope of my effort insofar as the
overall cancer rates have remained unchanged in the birth cohorts of the 20th-century. Of
course, it must be recognized that inherited conditions may well define sensitivity to
these known or unknown environmental risk factors. But whether genetic variation in
pharmacokinetic parameters, metabolism of specific environmental agents, reactions with
specific macromolecules or cellular and physiological responses to damage modulate
oncogenic mutation or preneoplastic growth rates cannot be distinguished among the set
of possible reasons for genetic risk for common diseases. Our effort is independent of the
arguments and data provided by Prof. W.G. Thilly, about causes of human somatic
mutations or their time of occurrence in a human lifetime (Muniappan and Thilly 2002;
Thilly 2003; Gostjeva and Thilly 2005; Zheng, Khrapko et al. 2006). Our goal is simply
to discover if, among the myriad of genetic possibilities, the hypothesis that familial risk
for a common cancer, e.g. CRC, is monogenic is excluded by existing observations.
Carcinogenesis Model
The carcinogenesis model we employ is a variant derived from Herrero-Jimenez'
collaboration with Prof. S. Morgenthaler and Prof. W.G. Thilly modified since 2000 by
their interactions with students and other researchers, especially Dr. E.V. Gostjeva. A
differential equation has been developed that, for each age t, accounts for the number of
expected cancer deaths, in which n oncomutations occurring in presumptive stem cells
early in life create preneoplastic colonies that grow at juvenile growth rates and mutation
(mutator) rates until a single preneoplastic stem cell has experienced m required onco-
events and gives rise to a clonal, rapidly growing lethal tumor. Their function PoBs (h, t)
represents the expected chance of cancer incidence in a cohort such as Swedish males
born in year h and observed at age t. The elements of this function need not be defined or
defended for my purposes. It need only be noted that the same function was expected to
apply to all persons at risk born in Sweden or the U.S. since 1900 and thus apply equally
to cohorts of "parents" and "children" identified in the Swedish Family Cancer Database.
3000
2500
2000
1500
1000
500
0
Birth Year
-- 1820s - -1830s
----- 1840s -- 1850s
--- 1860s -- 0-- 1870s
-- M----- iOM N1 1890s
---1---)0s ----- 1910s
- - -A--- 1920s --- A--- 1930s
--- o- - - 1940s --- --- -- 1950s
----- 1960s --.--- 1970s
--- X- -- 1980s
EAF
0 10 20 30 40 50 60 70 80 90 100 110
Age (years)
50nn
4500
4000
3500
3000
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100 110
Age (years)
FIGURE 1: (a) The age-specific mortality rate, OBS(t) from all malignant neoplasms
recorded between 1900 and 1997 for European American males. OBS(t) is calculated as
the observed number of deaths recorded in each calendar year in successive quinquennial
age-intervals, 0-4, 5-9,...,100-104, divided by the product of the number of persons alive
of that age interval and the fraction of persons surviving death by any cause in that
calendar year. OBS(t) is expressed as deaths from the observed disease, here all
malignant neoplasms, per 100,000 population. (b) OBS(t) for European American
females. These data are available at http://ePidemiologv.mit.edu.
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FIGURE 2: The age-specific mortality rate, OBS(t) from all malignant neoplasms
recorded between 1900 and 1997 for European American males born in the decades
1890-1899, 1900-1909, ..., 1980-1989. These data support an interpretation that the many
environmental changes of the 20th-century have had but minor effects on the overall
mortality rate from all malignant neoplasms, and that cohorts of parents and children born
in the 20th-century may be considered to have been at essentially identical environmental
risk.
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FIGURE 3: (a) The age-specific mortality rate, OBS(t) from all cancers of the lower
digestive tract that are comprised to an extent of -95% by colorectal cancers recorded
between 1900 and 1997 for European American males. OBS(t) is calculated as the
observed number of deaths recorded in each calendar year in age-intervals, 0-4, 5-
9,..., 100-104, divided by the product of the number of persons alive of that age interval
and the fraction of persons surviving death by any cause in that calendar year. OBS(t) is
expressed as deaths from the observed disease per 100,000 population. (b) OBS(t) for
European American females. These data are available at http://epidemiology.mit.edu.
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FIGURE 4: The age-specific mortality rate, OBS(t), from neoplasms of the lower
digestive tract recorded between 1900 and 1997 for European American males born in
the birth decades 1890-1899, 1900-1909,...,1980-1989. Maximum rates of the birth
decade cohorts of 1880-1889 and 1890-1899 declined in each successive decade, a
statistically significant decrease ascribable in part to a decreasing autopsy rate and
advances in medical practice.
FIGURE 5: The age-specific mortality rate, OBS(t), from neoplasms of the lower
digestive tract recorded between 1900 and 1997 for European American males born in
the decade 1890-1899 and corrected for historical increases in survival after diagnosis,
S(h,t), as in Herrero-Jimenez et al. (1998, 2000). Note that age-specific values are greater
than those for the crude mortality data of Figure 4.
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FIGURE 6: CRC incidence recorded as first time diagnoses of primary CRC among
Swedish fathers whose children were born 1932-2002 (Swedish Family Cancer Database.
Communicated by Prof. K. Hemminki, and prepared by Prof. W.G. Thilly).
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FIGURE 7: Distribution of colon cancer deaths among 520 Pennsylvania communities
recorded 1958-1997 among European American males aged 65-84. Histogram indicates
the observed[ distribution of mortality rates among communities whereas the continuous
black line indicates the sum of binomial distributions expected by chance for each
community. The expected and observed distributions were not significantly different
(Kolmogorov-Smirnov test) indicating that neither genetic nor environmental risk factors
for colon cancer differed significantly among these communities during the period of
observation (J.A. Vatland, MIT Ph.D. Thesis, 2001).
0
METHODOLOGY
Definition of terms
h: calendar year of birth
t: biological age at diagnosis
y = h + t : calendar year of diagnosis
0: subscript referring to the population of all parents or all children in Sweden (1958-
2002)
1: subscript referring to the subpopulation of all children with parents diagnosed with
CRC in Sweden (1958-2002)
Nh,: number of persons born in calendar year h
TOT(h,t): total mortality rate for birth year h and age t
INC(h, t) : crude age-specific incidence rate for birth year h and age at diagnosis t, i.e.
number of persons diagnosed with CRC for h and t, divided by the number of persons
alive for h and t
SUR(h,t) = S(h,t): fraction surviving observed disease after 5-yr interval
REP(h, t) = R(h, t) : fraction of reported deaths from specified causes
Poss (h, t) : expected chance of CRC incidence within group at risk
F(h, t): population fraction at primary risk for late-onset CRC
E(h,t): population fraction at environmental risk for late-onset CRC
G(h,t): population fraction at genetic risk for late-onset CRC
fh : fraction of persons at risk who would die of CRC in a fictitious population which is
at risk only from CRC and diseases sharing risk factors with CRC; fh increases, as
connected mortality decreases; fh accounts for competing forms of death, if any, with
the same risk factors as CRC
'late-onset': diagnosis at t 2 50
The data and assumptions about the values of the parameters that underlie age-
specific cancer incidence
For individuals in the Swedish Family Cancer Database (1958-2002), the values of
INC(h, t) have been unchanged as of h > 1900 for CRC. Thus, it is assumed that the
carcinogenic parameters are not historically variant, but constant, since 1900. For
simplicity, we drop the designation for birth year h, and combine CRC data within age
intervals t, regardless of h. The terms simplify to INC(t), TOT(t), S(t), R(t), Pos (t),
F(t), E(t), G(t), and f.
In this treatment, we assume that all persons at risk from CRC in the general Swedish
population are members of a single population at risk having identical carcinogenic
parameters S(t), R(t), Poss (t) and f . In particular, a child with late-onset CRC is
assumed to be a member of this population whether CRC is observed in either of its
parents or not. This assumption is supported by the observation that for the period
50 < t < 74, the age-specific CRC incidence rates are identical for the parents and
children in the general population.
TOT(t) is the total number of deaths in 5-year age intervals, 0-4, 5-9,...,90-94, divided
by the number of persons alive in the same year in calendar year y = h + t. It has been
introduced in the modeling equation to account for the expectation that other independent
forms of death compete with the observation of CRC, in particular given the obvious
significant increases in death rates in senectitude. Death rates from CRC would be but a
small fraction of total deaths in any interval, so that the differences between CRC rates in
those at risk., and those not at risk, are small, and can be ignored.
The observed diagnostic rate, corrected for competing forms of death, for birth year h
and age at CRC diagnosis t, is (Herrero-Jimenez, Thilly et al. 1998; Herrero-Jimenez,
Tomita-Mitchell et al. 2000):
INC(h, t) # DIAGNOSED(h, t)
I - TOT(h, t) #ALIVE(h,t) - (1- TOT(h, t))
1 as' (ht)(1-S (h,t))dt
Fh (1-,S(h,t)) -R(h,t) PoBs (h,t) e ] Nh
Fh I f PIs) (h,t)(1-S (Ih.t))dt ( - F )Fh e , +(1--Fh) N h
Simplifying and rearranging, this expression reduces to
INC(t) F -(I - S(t)) -R(t) - PoS (t)
1- TOT(t) - PO,,I (,•-S(t)dt
F +(1- F) e
This function provides fits with summed statistical variances equal to the sum of variance
for the observed values of INC(t) for most but not all common forms of cancer using data
from Sweden, the U.S. or Japan. Breast cancer is one exception, where the data suggest
superposition of incidences of two separate forms, arising in the mid 20s and mid 50s (P.
Herrero-Jimenez 2000, MIT Ph.D.Thesis).
Application of the function INC(t) to calculation of FRR(t); The importance of
independent definition of INC(t) according to gender
As shown in Figure 3 the age-specific mortality for cancers of the lower gastrointestinal
tract differ significantly between men and women. However, most familial data analyses
combine data for fathers and mothers as "parents" and sons and daughters as "children".
This creates an algebraic bias that needs to be addressed in order to reach an unbiased
estimate of genetic relative risk.
Consider letting the incidence for fathers be the number of paternal cases at age t be "A"
and the number of living fathers of that age be "B"; let the appropriate terms for mothers
be "C" and "D". When expressed as INC(t) as parents the term is calculated as
(A+B)/(C+D) when in fact the average rate among "parents" is (A/B + C/D)/2, which
terms are not equal to each other. As paternity is not established in an unknown
percentage of cases, which could be about 10% for children in the Swedish Family
Cancer Database, the fact that B<D adds another bias in the use of (A+B)/(C+D) as an
approximation of INC(t).
Another source of error in combining male and female data arises from the expectation
that the larger size of males provides them in the teenage years with a larger number of
tissue stem cells at risk of initiation, and thus larger lifetime values of POBS(t). Assuming
that males and females carry identical genetic risks, and experience nearly identical
environmental risks, the only term in the driving function for INC(t), FPoRs(t), is PoBs(t).
This point may be illustrated by considering the expected concordance of observed
disease in the sons or daughters of fathers or mothers with late-onset CRC. Sons would
appear to "inherit" CRC risk at a higher level than daughters because their values of
INC(t) are higher than their sisters' values.
It is clear that calculations of parent-to-child transmission on the basis of values of INC(t)
must be refined on the basis of father-to-son or mother-to-daughter transmission. The
ratios of age-specific incidences corrected for age-specific total mortality (which also
differs between men and women) should yield identical estimates of FRR(t) for both
genders.
In the following calculations and discussions, it is assumed that parent-to-child
relationships are defined as mother-to-daughter or father-to-son, anticipating the future
use of the Swedish Family Cancer Registry in this form. Father-to-son transmission will
be used in the examoles.
The corrected CRC diagnostic rate for fathers whose sons were diagnosed with CRC at
t > 50 is
F
, (I - S, (t)) R, (t). PoI (t)
F +Pls, (t)(-S F(t))dtFi + (1- F, ) -e
while the corrected CRC diagnostic rate for all fathers (as well as all sons) in the
population for t > 50, is
Fo (1- So (t))- Ro (t) PoBso (t)
The ratio of the observed incidence rates is
INC,(t) I - TOT,(t)
INCo (t) 1 - TOTo (t)
F
, *(1- S, (t))- R, (t)- POI sI(t)
Fo (1 - So(t)) -Ro (t) PORso (t)
Fo + (I- F0 )
Since 1930, the values of R(t) have been approximately 1. Survival S(h, t), likef, is
assumed to be approximately equal for the two subpopulations. The ratio of the observed
incidence rates thus simplifies to
INC, (t) F,
INCo(t) Fo
(1- e Pso (t)dtFo + (1- Fo) -e'
F, + (1- F,). e f
INC, (t)
1-TOT,(t)
INCo (t)
I - TOTo (t)
F,1 oBs, 
(t)( 1-S t (t))dt
F. + (1 - F. ).-e
+( )eA so , x-so- t)dl
F0 + (1- F0!'-e
I fPrSo(t)(1-S o(t))dt
-e
-IPs1 (t)dt
This ratio has interesting properties for the lowest and highest values of I fPoBs (t)dt.f
It increases asymptotically to a maximum, as1 os (t)dt increases with t.
The limit of this ratio as 1 fPoBs (t)dt -> o is a constant for given values of Ft and F0 .
I -(so t)dt
F, (1- Fo )- e' f OB
Fo F-F ) (t)dt(1-F1 ) e~
F, (1 - Fo)
Fo (I - F,)
For example, with Fo = 0.10, and F, = 0.25, whereby F, / F0 = 2.5,
INC, (t) 0.25 (1-0.10)INC (t) 0.10 (10.25 3.0
INCo(t) 0.10 (1-0.25)
IWhile algebraically interesting, values of -f fPoss (t)dt do not approach infinity in the
longest human lifespan, so that the value of INC1 (t) /INCo(t) is not expected to reach a
stable maximum in any father/son or mother/daughter comparisons.
Of more practical interest to us is the behavior of INC, (t) / INCo (t) for lower values of t,
for which the integral becomes vanishingly small, I fo- s (t)dt -+ 0.f
If PoBs (t)dt = 0, and f = I, then e' t)t = 1, and
INC, (t) F,
INCo (t) F0
Fo + (1- Fo)- e
F, + (1-F,).e
-I Bso (t)dt
_ F, Fo + (I - Fo) F,
oPsv (1) dt Fo  F, +(1 -F,) FoAY
INC, (t)
INCo (t)
Note that all stochastic processes embodied in the two-stage carcinogenesis model are
f Poso (t)dt
embodied in the term e1  , the probability of initiation in any potential age
"window", the competition with mortal diseases with shared environmental and genetic
risks, and the probability that any preneoplastic cell at risk of transformation may
transform at, any age after initiation. Thus, the stochastic processes that might bias the
estimate of Fi/Fo are found in both the denominator and numerator, given that father to
son or mother to daughter genetic transmissions are rigorously defined. This important
algebraic "canceling out" of these complex terms is clearly dependent on same gender
genetic transmission of risk as INC(t) differs significantly between males and females
SPoso (d t dt
presumably because of differences in the values of e'
For colorectal cancer, f - 1 appears to be a valid assumption with regard to risk from
other common cancers. The range of values of f was based on findings of limited risk
sharing between CRC and other cancers (Gruber, Ellis et al. 2002; Meijers-Heijboer,
Wijnen et all. 2003; Hemminki and Chen 2004; Hemminki and Chen 2004). There is no
current knowledge about shared risks with non-cancer fatal diseases, such as vascular
diseases, which account for nearly half of all current deaths from persons over 50. We
thus assume pro tempore that there are no significant shared inherited risks for
cardiovascular diseases and CRC, and that the assumption f = I holds.
In an independent study relevant to this assumption Prof. W.G. Thilly has explored
possible values of I fos (t)dt for values of f = 0.8 - 1.0 using the estimated CRC
mLR for Swedish males of >0.26 and the Java-based program CancerFit4_l.xls
developed and employed by his group. His communication is given here:
" The observations ofAtkin you cite indicate that males with adenomatous polyps have
about 1.3 polyps per person and I believe you have correctly estimated the fraction of
males at risk of polyps to be about I- e-0 55 = 0.427. This estimate of the fraction of males
at risk of tumor initiation that experience tumor initiation fixes the initiation rate
parameter, Cini,, at a value of about 0.005. I have calculated that this value would lead to
an inactivated mutant fraction for a gene in which CRC initiation mutations occur, such
as APC, to be at about 2 x 10-4 at maturity. This estimate is in accord with the
observation of several thousands of polyps in adults with FAPC syndrome and 6-10 x 106
colonic crypts. Thus I have used this value, Cini, 0.005, and the estimate of a constant
preneoplastic growth rate of -0. 1-0.15, 0.26<F<1.0 and 0.6<f< 1.0 to determine if your
statement that in the age intervals 50-54, ..., 70-74 the term (1/ f ) JPos (t)dt is small,
approximating zero for Swedish or European American males. Applying this estimate to
the Swedish parents data, we note that values of PoBs (t) for all t are essentially
invariant with F and f, and thus that JPoBs (t)dt may be calculated for all values of t.
For t < 75, JPoBs (t)dt = 0.035 = 0. Your assumption in this regard appears to be
justified. "
The finding that Poss (t)dt =0.035 = 0 for t<75 was crucial for the ratios
INC, (t) / INCo (t) at t = 50-54, 55-59, 60-64, 65-69, and 70-74 to each be app. equal to
F, I Fo = FRR(t; 50 • t < 75). The validity of the approximation having been tested and
delimited, we conclude, subject to uncertainty in the potential interactive role of
cardiovascular disease in these age intervals, that the ratio of the CRC incidence rates for
quinquennial age intervals within 50 < t < 75, is approximately equal to the ratio of the
population fractions at risk, i.e. the familial relative risk for late-onset disease.
INC, (t) F, Fo+(1-Fo) 1 F= . - I = FRR(t; 50 5 t < 75)
INCo (t) Fo F, +(I-F,). I  Fo
Let's note that FRR(t; 50 t < 75) may not be reasonably called 'late-onset'
FRR(t; late - onset), insofar as these age intervals are strictly defined, but an early subset
of 'late-onset'.
Familial risk may arise from shared genetic background and/or shared environmental
experiences. We address etiologic apportionment in the following section.
Accounting for Environmental Risk
The historical increase in CRC rates occurred in narrow historical time windows. For
birth cohorts in the United States and Western Europe, including Sweden, after 1890-
1900, incidence and mortality data for colorectal cancer indicate that peak age-specific
rates have reached a stable plateau, a local maximum in mathematical terms. The changes
that led to these increases were likely to be environmental and not genetic, since
population genetic changes take longer on the evolutionary scale. From some historical
time on, the environment is having a uniform effect, and does not account for risk
differences.
These considerations suggest that the persons registered in the Swedish Family Cancer
Database (1958-2002) experienced homogeneous environmental risk, throughout the
historical period of their birth cohorts. Lung cancer is, of course, exempted from this
assumption. In quantitative terms, the fraction of subpopulations at environmental risk is
the same, Eo = E, = E. In particular, the fraction at environmental risk is the same for
those with and those without family history of a particular form of cancer. Since the
fraction of a population at overall risk comprises the intersection of the fractions at
environmental and genetic risk, Ft = EG, and Fo = EGO, it follows that the late-onset
familial relative risk is approximately equal to the genotype or genetic relative risk,
FRR(t; late -onset) = F, / Fo = G, / Go = GRR . Therefore, the differences between the
general population and the subpopulation with a family history of common cancer are
reasonably attributed to differences in genetic makeup.
FRR(t; late - onset) - FL _ E = EG - G• GRR
Fo Eo -Go E -Go Go
INC, (t; late - onset) t= FRR(t; late - onset) = GRR
INCo (t; late - onset)
Original to this thesis is the recognition of the importance of employing strictly gender-
specific data and age-specific data comprising ages 50-54,...,70-74, in calculating the
familial risk for late-onset common diseases such as CRC. Combination of this advance
with the observations of Dr. J.A. Vatland (no difference in CRC or any other cancer risk
among communities in any of several U.S. states), the Hemminki group (no spousal risk
for CRC or most other cancers) and the observation that age-specific risk for CRC and
most other cancers has remained invariant in the U.S. and Sweden for birth year cohorts
since 1900, have permitted us to conclude that there are no generational differences in
environmental risk in the Swedish Family Cancer Database, and that FRR(t; late -onset)
for father-to-son and mother-to-daughter transmission of risk, yields the desired estimates
of genetic relative risk, GRR.
Comments: Age-specific Familial Relative Risk, FRR(t), in Sweden
The Swedish Family-Cancer Database (1958-2002) provides age-specific incidence rates
for individual forms of cancers in the general population of all children born since
January 1, 1932, and their biological parents. These two age-specific cancer incidence
rates are practically identical for age intervals up to 65-69, the oldest interval for which
data from "children" born 1932-1936 are available.
For colorectal cancer and many other cancers, these age-specific incidence curves rise
exponentially from teenage years into the 70s, reach a maximum around 90, and decline
significantly by the age interval 100-104. The decline in incidence in old age was
clinically confirmed by serial autopsies of deaths in the Swedish state of Malm6, for
about twenty to twenty-five years.
As noted above the minimum lifetime risk, mLR, may be calculated from the age-specific
incidence data for any disease as the area under the incidence curve from age zero to a
theoretical age when incidence rates would have declined to zero (Herrero-Jimenez,
Thilly et al. 1998; Herrero-Jimenez, Tomita-Mitchell et al. 2000). It is a composite
function of the fractions of the population at genetic (G), environmental (E), and
stochastic risk, as well as any fatal condition that shares the risk factors of the observed
disease - the relevant parameter here beingf, which accounts for mortality from other
diseases sharing the risk factors of the observed disease. Multistage models of
carcinogenesis allow estimation of F, but absent independent determinations of E andf,
values of the fraction at genetic risk (G), cannot be determined from the age-specific
incidence data alone.
For colorectal cancer, the area under the curve for combined data of Swedish males and
females is about 0.26 as calculated from the area under the curve of Figure 6 above. The
fraction at environmental risk (E), is as noted, apparently uniform among successive birth
cohorts in the present-day Swedish population. Supporting evidence for this assertion
comes from (i) mLR having reached a stable maximum since the birth cohort of 1900, (ii)
lack of spousal risk for colorectal cancer in Sweden and (iii) no apparent risk sharing
between colorectal cancer and many other common forms of mortality. E may or may not
be close to 1. In the case of E < 1, familial genetic risk as defined above can still be
estimated as the values of FRR(t) for age intervals t = 50-54,..., 70-74, since E is found as
a factor in both the numerator and denominator in the definition of FRR(t). (N.B. Spousal
concordant risks have been found for late-onset stomach cancer, lung cancer, genital
cancers and melanoma.)
Considered ranges for Go 2mLR, q, and FRR (t = 50-54,...,70-74)
The values of mLR are higher than that of CRC for prostate, breast, and lung cancer, and
lower than CRC for most other cancers. Thus, it is necessary to account for values of Go_?
mLR from 0.01 to 1.00, with the corresponding values of q and FRR (t = 50-54,..., 70-74),
explored and summarized in tables. The values of q have been considered over the entire
possible range, 0 to 1.0. The values of FRR (t = 50-54,..., 70-74) have been considered at
1.5, 2.0, 2.5., and 3.0, encompassing estimates from the Hemminki group for a wide
variety of late-onset cancer forms. Acceptable values for any cancer type are those for
which (i) G(, is equal to or greater than mLR, and (ii) GRR is approximately equal to
FRR(t; late -- onset). Limits on q are not applied even though the 99% ucl on q for genes
carrying non-deleterious mutations is about 0.22 (Morgenthaler and Thilly 2006). This is
because with -5000 genes that could carry non-deleterious gene-inactivating mutations
some 50 would be expected to have q>0.22, sufficient to force consideration of
monogenic risk-conferring values of q from 0.22 to 1.0.
Age-specific familial risk, FRR(t), for CRC and other cancers has been defined variously
in the scientific literature. In some publications, it is meant to be equivalent to the integral
of the age-specific incidence in parents of children or in children of parents with a
particular form of cancer. For CRC in the Swedish population, the age-specific CRC
incidence in children with parents diagnosed with CRC, and that in parents with children
diagnosed with CRC, are identical for age intervals up to 65-69, the oldest ages currently
available in the 1958-2002 version of the database, for cohorts born in or after 1932. It is
clear for the available age intervals that the CRC incidence in children whose parents are
diagnosed with CRC is higher than the incidence in the population of all children,
creating a prima facie case for CRC familial risk. Given the indications that E is identical
in the parental (male or female) and offspring (male or female) cohorts for CRC in
Sweden, these data suggest that CRC familial risk is attributable to mainly genetic
causes. A more extensive discussion can be found in Hemminki and Chen (2004).
Defining the actual numerical value of FRR(t) for CRC or any other disease presents a
challenge, and is the focus of renewed effort in the collaboration within and between the
Hemminki and Thilly groups.
A main problem is that except for sporadic efforts, e.g. for endometrial cancer
(Hemminki, Vaittinen et al. 1999), for gastric cancer (Hemminki and Jiang 2002), and for
colorectal adenocarcinoma (Hemminki and Chen 2004), cases of early-onset CRC are
admixed with late-onset CRC in calculating overall and age-specific familial risk.
However, as there are known genetic conditions conferring early risk for CRC, such as
familial adenomatous polyposis (FAP) with a mean age of onset of 39, and hereditary
non-polyposis colorectal cancer (HNPCC, Lynch syndrome) with a mean age of onset of
44, the definition of late-onset CRC familial risk requires that parent-child shared risks be
calculated for late-onset CRC alone. In the 1998 version of the Swedish Family Cancer
Database, some 40% of offspring CRC cases were under the age of 50, creating potential
bias in estimating familial risk for late-onset CRC. The process of sorting out the age-
specific incidence in cases where CRC is detected in parents and children of age 50 or
greater is in progress. When this is completed, a reasonable estimate may be obtained for
values of FRR(t) in male offspring of male parents with late-onset CRC, or female
offspring of female parents with late-onset CRC. i.e. diagnosed at age 50 or older.
As there are no calculated values available at this time point we have made an educated
guess of 1.5-3.0 for GRR in colorectal cancer and calculate the values of GRR over a
wide set (1.5, 2.0, 2.5, 3.0), in order to encompass a broad set of possibilities for various
common diseases.
Considered Modes of Inherited Risk
The possibilities of genetic risk considered are heterozygosity and nullizygosity (the
latter usually referred to as recessive inheritance in the literature), for one or more genes
acting independently, each in a sufficient but not necessary mode (multigenically, i.e. in
series), or coordinately, in a necessary but not sufficient mode (polygenically, i.e. in
parallel), to confer risk for the disease under study.
Formal expressions for genetic relative risk, for autosomal and sex-linked monogenic
disorders, were previously derived for any kind of relatives, using stochastic matrices (Li
and Sacks 1954). Another method to obtain such expressions is using path analysis. Yet
another approach is via mating tables, where parental and offspring combinations are
enumerated, probabilities are calculated, and values are summated; this approach allows a
more tractable extension to multigenic and polygenic modes of inheritance.
First, the basic algebra for monogenic disorders is presented for risk conferred by
heterozygous or nullizygous conditions. Derivations, ranges of values, figures, and tables
are given, emphasizing the relationship between and q and Go, Go and GRR, and q and
GRR, for each possible mode of inheritance.
Second, in a similar but more elaborate manner, the basic algebra for multigenic
disorders is presented. Derivations are lengthier, closed formule are given, and more
refined formulae are calculated for levels of muligenicity from 2 to 5 genes.
Third, the basic algebra for polygenic disorders is presented. General formulae are
obtained, that can yield values for any number of genes.
Given these several but distinct formal relationships, we consider how they may be used
to delimit the modes of inheritance of risk for a particular form of late-onset cancer, using
CRC as an example.
FAMILIAL RELATIVE RISK
As derived above, the genetic relative risk, GRR, is observed as the ratios of incidence at
ages 50-54, 55-59,...,70-74, among the fathers of sons, or mothers of daughters with a
particular common disease at age t > 50, to the incidence of that disease in those age
intervals for all fathers and mothers respectively. Environmental risks appear to be equal
in both generations, and stochastic risks are assumed to be the same among persons of the
same gender in both generations compared. That is:
GRR - FRR(t = 50 - 54,...,70 - 74) =INC (t =50-54,...,70- 74)
INCo (t = 50 - 54,...,70 - 74)
Formally, GRR is also the ratio of genetic risk, G,, in fathers of sons, or mothers of
daughters with incidence at t 2 50, to the general genetic risk, Go . That is:
GRR = G, / G
These two relationships for GRR permit us to calculate expected values of GRR for any
estimated value of Go. Recall that:
Go = F I E > Fo  mLR
Thus, for any observed value of mLR, which is the area under the curve INC(t) versus t in
the general population of male or female parents, we may posit that all values of Go equal
to or greater than mLR are possible, and that for an observed value of GRR the set of all
values of G, are thus approximated.
Formal forms of Mendelian risk may thus be evaluated to discover if any of the possible
values of GRR are consistent with the specifically posited form of genetic risk.
Risk may vary with regard to the number of genes conferring risk for a particular disease
independently or in concert. Risk conferred by a mutation or mutations in that gene
distributed over the general population is termed "monogenic risk".
Risk conferred by any of m genes each independently carrying risk-conferring mutations
is termed "multigenic risk". Risk conferred by any of n genes carrying risk-conferring
mutations but acting together to create risk is termed "polygenic risk".
The formal Mendelian definitions of the "zygosity" of the genetic risk apply. If an
individual to be at genetic risk must carry gene-inactivating, risk-conferring mutations in
both copies of an autosomal gene then the risk is termed "nullizygous". If two active
copies are required for risk, it is termed "homozygous risk". If one active and one
inactivated copy is required to define risk, it is termed "heterozygous risk".
There are, of course, a very large number of possible combinations of genetic risk, such
as polygenic risks, each element of which consists of several multigenic risks.
To present a careful analysis of these possibilities, we have restricted our analyses to
monogenic and simplified sets of multigenic and polygenic risk. For each condition, we
have derived the explicit equation for Go for any values of q (fraction of inactivated, risk-
conferring alleles) for any number of genes considered, but have also calculated explicit
values for q, under the simplifying assumption that q is the same for all genes.
These points having been explained, we now present the formulae we have derived for
the various forms of genetic risk relating Go to q, GRR to q, and GRR to Go. These
formulae are then in turn applied to create tables by which the possible values of Go >
mLR and GRR are used to discover if they exclude one or more of the formal genetic
possibilities considered. Among those possibilities that are not excluded, the resulting
estimates of q are then considered in terms of the expectation that genes conferring risk
for common diseases have a mean value of q of about 0.03 and a 99% u.c.l. of about 0.22.
I. MONOGENIC RISK
1. Monogenic Heterozygous Risk: A'/-
[Figures 8.1-8.4 and Table 1]
General genetic risk:
Go = 2pq = 2q(l- q)
2q 2 -2q + G0 = 0
q= (l -2Go)/2
Transmission of risk:
Mating: Al'- x (A'+', A'/-, A-'-).
G I = P(any child is A''-) = 0.5
G1 is the same for either one or two afflicted parents
0.5 0.5GRR = - - with either 1
Go 2pq
or 2 affected parents
Limitations on value of Go:
Go < 0.5 = 1/ 2 as the maximum fraction of heterozygotes is 1/2 for all values of q
2. Monogenic Nullizygous Risk: A-/-
General genetic risk:
Go =q 2
Transmission of risk:
Mating: A-'- x (A+ '+ , A +/- , A-' - )
GI differs for one vs. two afflicted parents
i. One affected parent [Figures 9.1-9.4 and Table 2]
Mating: A-'- x (A"' , A+/- , A-' - )
G1= P(any child is A-'-)= O. p2 +-2pq + q =pq + q =q(p+q)=q2
GRR = G  q - I I
Go q2  q 4o
1 IGRR = q
ii. Two affected parents
Mating: A-'- x A- '-
G I= P(any child is A-'- ) = 1
1 1GRR = Go q2
No limitations on value of Go for monogenic nullizygous risk:
Go may have any value from 0 to I
II. MULTIGENIC RISK (OR)
The inclusion-exclusion formula of probability has been used to define the expected
values of GRR for the specific examples. Risk may be conferred by carrying mutations in
one or more of n > 1 genes but mutation in any one of n genes is sufficient to create risk.
1. Multigenic Heterozygous Risk: A1+'- OR A2 '/ - OR ... OR Am+/-
i. m = 2 [Figures 10.1-10.4 and Table 3]
General genetic risk:
Go= 2p,q, + 2p 2q2 -(2pjq,)(2p 2q2)
Transmission of risk:
GI = [0.5 + 2pq 2 - (0.5)(2p,q2) ][2plql/(2plql+2p2q2)] +
[0.5 + 2p1q, - (0.5)(2pq) ] [2p2q2/(2plql+2p2q2)]
GRR = { [0.5 + 2p2 q2 - (0.5)(2P2 q2 )][2plql/(2plql+2p2q2)] +
[0.5 + 2p qc - (0.5)(2pq) ] [2p2q2/(2plql+2p2q2)] } /
[2pq, + 2P2q2 - (2pq,)(2P2q2 )]
Simplification for calculation: q, = q
Then,
GRR G, 0.5 + pq 0.5 + pq
Go  2(2pq)-(2pq)' 1-(I- 2pq)2
q = [l+ l-2- (1- -Go )]/ 2
Limitations on value of Go:
As the maximum fraction of heterozygotes is 1/2 for each of the two genes conferring
risk, a limit exists for the maximum genetic risk that may be created by two genes
independently conferring heterozygous risk:
Go < 0.75 = 3/4
ii. m = 3 [Figures 11.1-11.4 and Table 4]
General genetic risk:
G = : 1(2pq) - 3 (2 piq)(2pjqj) + (2pq, )(2Pq 2 )(2p 3q3) = 2pq, + 2 2q2 + 2p 3q 3
- (2pq,)(2p2q 2)-(2p1q )(2P 3q3)- (2P2 q2 )(2P 3q3)+ (2plq1 )(2P 2q2)(2P3q 3)
Transmission of risk:
G1 = [2plq/l(2plql+2p 2q2+2p3q3)] X
[0.5 + 2pzq 2 + 2p 3q3 - (0.5)(2p2q 2 + 2p 3q3)- (2p 2q2)(2p 3q3)+ (0.5)(2p,q,)(2p 3q3)] +
[2p2q2/(2plql+2p2q2 +2p3q3)] X
[ 0.5 + 2pqc + 2p 3q3 - (0.5)(2pq, + 2P 3q3)- (2pq2)(2pq3)+ (0.5)(2p q,)(2p 3q3)] +
[2p3q3/(2plql+2p2q2 +2p3q3)] X
[ 0.5 + 2pjq + 2P2q 2 - (0.5)(2pql + 2 P2q2) - (2plq, )(2p 2q2) + (0.5)(2p q,)(2pq 2)
Simplification for calculation: qi = q
Then,
GRR G, 0.5 + 2pq - 2p 2q 2  1- 0.5(1- 2pq)2
GO  3(2pq)- 3(2pq)2 + (2pq)3  1- (I - 2pq)3
q= [l+J -2(-- ]-G )]/2
Limitations on value of Go:
As the maximum fraction of heterozygotes is 1/2 for each of the three genes conferring
risk, a limit exists for the maximum genetic risk that may be created by three genes
independently conferring heterozygous risk:
Go < 0.875 = 7/8
iii. m = 4 [Figures 12.1-12.4 and Table 5]
Similar terms may be defined for the exact expected values of Go and G1 for all values of
m but absent values of q for any of the genes, we here summarize the results using q, = q
for m = 4 and m = 5 that are used in my calculations:
GRR G  I - 0.5(1- 2pq)3
Go  1-(1-2pq) 4
q= [l+ l 2(1F-4 -G)] /2
Limitations on value of Go:
As the maximum fraction of heterozygotes is 1/2 for each of the four genes conferring
risk, a limit exists for the maximum genetic risk that may be created by four genes
independently conferring heterozygous risk:
Go  0.9375 =15/16
iv. m = 5 [Figures 13.1-13.4 and Table 6]
Assuming qi = q:
SG  1-0.5(1-2pq) 4
Go I--( 1-2pq)5
q = [l I-- 2(1- ) ]/ 2
Limitations on value of Go:
As the maximum fraction of heterozygotes is 1/2 for each of the five genes conferring
risk, a limit exists for the maximum genetic risk that may be created by five genes
independently conferring heterozygous risk:
Go 50.96875 = 31/32
v. m>5
General calculations for multigenic heterozygous risk
Set 0.5 = 2 p,,q,, for indexing in the numerator (*) - no biological interpretation
0.5 + Ii> (2piqj) - ,(2piqi)(2pjqj) +...+ (-)m (0.5)(2P2q2)...(2pmqm)
GRR =
i=(21pq,) - (2Piqi)(p 2pq) +...+ (-)' (2ptq,)(2p 2q2)...(2pmqm)
q for the following calculations for GRR = Gi/Go
m For the numerator, there are + combinatorial terms
: For the numerator, there are kcombinatorial terms
G,= [.5 + (m - 1)(2 pq)]- (m - 1)( 2pq) + 2 (2pq)2[ m-1
+ M 1 (0.5)(2pq)2 3+ m- (2pq)3 M]-i J(0.5)(2 p q )3 + mr-1 (2pq)'
+...+ (-1) (0.5)(2pq)k-• + j(2pq)k
1k- - k
G, = 1- 0.5 + (m - 1)(0.5)(2pq)- M2 (0.5)(2pq)
+ I -(0.5)(2pq)3 +...+ (- 1 (0.5)(2pq)k (0...5)(2 pq)M-1
G,= 10.5 (-2pq)j =li=0( 1 1- 0.5(1- 2pq)"-
1
-: For the denominator,
Go = m(2pq)- 2 (2pq)2 + )(2pq)3 +...+(_1)k-
Go = - (-22pq)'j=t J
=1- .( -2pq) = - ( - 2pq) "
The ratio, given the assumption qi q, reduces to:
G, I -0.5(1 - 2pq)m-' 1-0.5(1 -Go 0)l/nz
GRR =2pq)
Go I-(1-2pq)" Go
+... + (-1)n (0.5)(2pq)m- '
(2pq) k +...+(-1)m-L(2pq) m
Comments on multigenic heterozygous risk
GRR is a decreasing function of Go , for a given m.
1- 0.5(1- 2pq)m-1
1- (1- 2pq)(1- 2pq)'-'
GRR is a symmetric bathtub function of q, for a given m.
It is symmetric about q = 0.5, where it attains the minimum value 1.
: 2pq 0.5
€+ q = 0.5
=:> - 2pq 20.5 => GRR > 1
Range of values
q 10, q T 1: GRR ->oo
0 < q • 0.5 GRR 1
0.5 < q < I GRR "
Expression for q in terms of Go
Go = - (1--2pq)'"
(I - 2pq)'" = 1- Go
1-2pq=m 1-G o - 2   J1 - Go
2pq = 1 - J1 -Go
2q(1-q) = 1 - V1-G 0
2q 2 -2q+(I -~ - )Go =0
GRR =
GRR = 1
q=[[1 + -- 2 ( 1- mV - ) ] / 2
Limitations on value of Go:
As the maximum fraction of heterozygotes is 1/2 for each of the m genes conferring risk,
a limit exists for the maximum genetic risk that may be created by m genes independently
conferring heterozygous risk:
Go <1-0.5
m
"
2. Multigen.ic Nullizygous Risk: Ai' /- OR A2-/- OR ... OR Am-/-
Only calculations for one affected parent have been made. A briefer text format is now
used to avoid even more tedious repetitions.
i. m = 2 [Figures 14.1-14.4 and Table 7]
Go = qI + qI -q q2
G1 = q, + q; -qtq;
qI +q 2 - qjq 2GRR = +
q + q - q2q;
For the simplifying condition, q = q :
GRR= G  = q + q 2 -q 3 - -(- q)(-q 2)
Go 2q2 -q 4  1-(1-q )2
and
q = 1-I - G0
ii. m = 3 [Figures 15.1-15.4 and Table 8]
2 2 2 2 2 22Go= q + q2 + q3 -qq2 - qq3 -q2q +ql 2q 3
GR = q1 +q2 +q2 -qjq 2 - qq32 -qq +qq 1 q1 3
2 2 2 22 2• 22q1 +q +q 3 -q q2 - ql q - qq + q 2q 3
For the simplifying condition, qi = q:
q + 2q2 - 2q3 -q 4 + q5
3q 2 - 3q 4 + q 6
1-(1- - q2 )2
1-(l-q 2)3
and
q= 1•-3 -G 0
iii. m = 4 [Figures 16.1-16.4 and Table 9]
For the simplifying condition, qi = q :
GRR = G =-(-q)(I-q2)3
Go I1- (1-q 2 )4
and
q= 1-Ii-Go.
iv. m = 5 [Figures 17.1-17.4 and Table 10]
For the simplifying condition, qi = q:
GRR = G = -(-q)(-q2)4
Go I-( 1-q 2 )5
and
q=v. m>5
v. m>5
General calculations for multigenic nullizygous risk
Setting q, = q,, just for indexing in the numerator (*) - no biological interpretation
q, + .>• .qm(q ) k(q 2 q)+m-, 2 q 2
GRR =
m 2 22 2 2 2 m- 1 2 2 2 2kj i i j<k
GRR = G
t
Go
q for the following calculations
[-•]: For the numerator,
(m-1)q3 + 42
M2lq + M3 jq62 3
2k+ + - 2k+2(
GI = q + (m-l1)(q2 _q3 1(q 4
+ ... -q)+ (m- )q 2(k-q
G, = 1-(1-q)+(m-1)q 2(l-q)
m-1 6 7)
q 2k+l) + m-(_l) 1 - 2m-I
- 2 q4(l q)
+...+ ( 1)k+ m 2k
k qk
N: For the denominator,
Go =mq2 - mj 4 + jq6 J ( _ 1q)2 __ q 2 )m+...+(l)m-1 q 2m
G = q+(m-1)q 2]
GRR = G -- (1--q)(--q ) m- I-(I - 1 I - G°)((l - G°)-GO 1 - (1 - q 2)1 Go
m- m-G q = l -( 1 1q) (-q1 2i - - Xl 2 )m-1
i=o
Comments on multigenic nullizygous risk
GRR is a decreasing function ofG 0 , for a given m
1 - (1 - q)(1 - q2 )m-1fGRR =
1 - (I - q2 X)(I - q2 )m-1
GRR is a decreasing function of q, for a given m.
O<q<l := q>q
Range of values for GRR
q ·1 0: GRR loi
ql Tl: GRR ->
Expression for q in terms of Go
Go = 1-(1--q2) 
m
( - q 2 )m = -G o
1-q 2 =m f.-Go
q2 = 1 - i-Go
Given G0,
mi q 1 GRR -
-> -q<l-q 2 => GRR>I
III. POLYGENIC RISK (AND)
1. Polygenic Heterozygous Risk: A1+/-' AND A2+/ - AND ... AND A, +/-
GO =fln(2piqi )
G1= 0.5"
0.5"nGRR =
Go
0.5"
(2 pq, )(2p 2 q2 )...(2p,q,, )
For the simplifying assumption qi = q,
GRR 0.5" 0.5GRR= =
0Go 2pq
G/" = 2pq= 2q(1 -q)
2q 2 - 2q +G t" = 0
q = (fi 2G'/")/2
Limitations on value of Go:
< 0.5Go : 0.5"n
For the case n = 2,
[Figures 18.1-18.4 and Table 11]
(0.5)(0.5)GRR 2
(2pq, )(2P2q 2)
0.5
(2pq)2
where Go(n = 2) • 0.25.
0.5"
Jf(2piqi)
0.25
Go
2. Polygenic Nullizygous Risk: A1/- AND A2-'- OR ... AND A - -
i. One affected parent [Figures 19.1-19.4 and Tables 12-13]
Generally,
Go = q 2 q3 ... qn
G, = q -(qq 3...q,,)
G, - q, * (q2q3...q,) 1 1 1GRR =q Go qq q2q3 .. ,, 2.. q, ]Iq "o
If qi q, then
I 1
GRR = -
,4[--7 qn
ii. Two affected parents
Generally,
Go= 1
G, = Hq
1 1 1
GRR =-
Go qq2q3 .. qT , q
If qi q, then
1 1
GRR =
With either one or two affected parents,
Go =q 2n
q = G1i2n
GRAPHIC AND TABULAR PRESENTATION OF CALCULATED
RELATIONSHIPS
The values obtained for each mode of genetic transmission addressed above are presented
in this section. The observed values corresponding to FRR (t = 50-54,...,70-74), by which
GRR is approximated, are considered at the specific values of 1.5, 2.0, 2.5 and 3.0 which
encompasses the estimates made to date by the Hemminki group for various common
late-onset forms of cancer including colorectal cancer, CRC. When the data of the
Swedish family cancer register are calculated to yield gender specific values of FRR (t =
50-54,...,70-74) for specific cancers these tables may be used with the estimate of Go >
mLR to discover for each cancer type if any mode of Mendelian inheritance is excluded.
As an example, we consider the case of colorectal cancer in Swedish male parents from
which we derived (Figure 6) a value of mLR of 0.26 and from several reports of the
Hemminki group of an estimate of GRR for colorectal cancer between 1.5 and 3.0. This
estimate of GRR for colorectal cancer is under refinement now by the collaborating
groups but our contribution is to set up the logical structure that would permit arithmetic
exclusion of particular Mendelian modes for any disease for which estimates of mLR and
GRR were made.
Please note that for the following figures, the variable G actually indicates Go.
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FIGURE 9.1. G vs q; monogenic nullizygous risk - 1 parent
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FIGURE 9.3. GRR vs G; monogenic nullizygous risk - 1 parent
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FIGURE 9.4. GRR vs G; monogenic nullizygous risk - 1 parent
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FIGURE 10.1. G vs q; multigenic heterozygous risk, m=2
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FIGURE 10.2. GRR vs q; multigenic heterozygous risk, m=2
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FIGURE 11.1. G vs q; multigenic heterozygous risk, m=3
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FIGURE 11.2. GRR vs q; multigenic heterozygous risk, m=3
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FIGURE 11.3. GRR vs G; multigenic heterozygous risk, m=3
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FIGURE 12.3. GRR vs G; multigenic heterozygous risk, m=4
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FIGURE 13.4. GRR vs G; multigenic heterozygous risk, m=5
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FIGURE 14.1. G vs q; multigenic nullizygous risk, m=2
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FIGURE 14.3. GRR vs G; multigenic nullizygous risk, m=2
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FIGURE 15.1. G vs q; multigenic nullizygous risk, m=3
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FIGURE 15.3. GRR vs G; multigenic nullizygous risk, m=3
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FIGURE 15.4. GRR vs G; multigenic nullizygous risk, m=3
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FIGURE 16.1. G vs q; multigenic nullizygous risk, m=4
FIGURE 16.2. GRR vs q; multigenic nullizygous risk, m=4
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FIGURE 16.4. GRR vs G; multigenic nullizygous risk, m=4
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FIGURE 17.2. GRR vs q; multigenic nullizygous risk, m=5
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FIGURE 17.1. G vs q; multigenic nullizygous risk, m=5
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FIGURE 17.3. GRR vs G; multigenic nullizygous risk, m=5
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FIGURE 17.4. GRR vs G; multigenic nullizygous risk, m=5
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FIGURE 18.1. G vs q; polygenic heterozygous risk, n=2
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FIGURE 18.3. GRR vs G; polygenic heterozygous risk, n=2
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FIGURE 19.1. G vs q; polygenic nullizygous risk, n=2, 5, 15, 25
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FIGURE 19.2. GRR vs q; polygenic nullizygous risk, n=2, 5, 15, 25
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FIGURE 19.3. GRR vs G; polygenic nullizygous risk - 1 parent
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TABLE 1: Monogenic heterozygous risk (Go <0.5)
Go q 1-q GRR
0.01 0.00503 0.99497 50
0.02 0.01010 0.98990 25
0.03 0.01523 0.98477 16.6667
0.04 0.02042 0.97958 12.5
0.05 0.02566 0.97434 10
0.06 0.03096 0.96904 8.3333
0.07 0.03632 0.96368 7.1429
0.08 0.04174 0.95826 6.25
0.09 0.04723 0.95277 5.5556
0.1 0.05279 0.94721 5
0.11 0.05841 0.94159 4.5455
0.12 0.06411 0.93589 4.1667
0.13 0.06988 0.93012 3.8462
0.14 0.07574 0.92426 3.5714
0.15 0.08167 0.91833 3.3333
0.16 0.08769 0.91231 3.125
0.1667 0.09175 0.90825 3
0.17 0.09380 0.90620 2.9412
0.18 0.1 0.9 2.7778
0.19 0.10630 0.89370 2.6316
0.2 0.11270 0.88730 2.5
0.21 0.11921 0.88079 2.3810
0.22 0.12583 0.87417 2.2727
0.23 0.13258 0.86742 2.1739
0.24 0.13944 0.86056 2.0833
0.25 0.14645 0.85355 2
0.26 0.15359 0.84641 1.9231
0.27 0.16088 0.83912 1.8519
0.28 0.16834 0.83166 1.7857
0.29 0.17596 0.82404 1.7241
0.3 0.18377 0.81623 1.6667
0.31 0.19178 0.80822 1.6129
0.32 0.2 0.8 1.5625
TABLE 1 cont'd: Monogenic heterozygous risk (Go < 0.5)
Go q 1-q GRR
0.33 0.20845 0.79155 1.5152
0.3333 0.21132 0.78868 1.5
0.34 0.21716 0.78284 1.4706
0.35 0.22614 0.77386 1.4286
0.36 0.23542 0.76458 1.3889
0.37 0.24505 0.75495 1.3514
0.38 0.25505 0.74495 1.3158
0.39 0.26548 0.73452 1.2821
0.4 0.27639 0.72361 1.25
0.41 0.28787 0.71213 1.2195
0.42 0.3 0.7 1.1905
0.43 0.31292 0.68708 1.1628
0.44 0.32679 0.67321 1.1364
0.45 0.34189 0.65811 1.1111
0.46 0.35858 0.64142 1.0870
0.47 0.37753 0.62247 1.0638
0.48 0.4 0.6 1.0417
0.49 0.42929 0.57071 1.0204
0.5 0.5 0.5 1
TABLE 2: Monogenic nullizygous risk
Go
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0.11
0.1111
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.32
GRR (1 parent)
10
7.0711
5.7735
5
4.4721
4.0825
3.7796
3.5355
3.3333
3.1623
3.0151
q
0.1
0.14142
0.17321
0.2
0.22361
0.24495
0.26458
0.28284
0.3
0.31623
0.33166
0.33333
0.34641
0.36056
0.37417
0.38730
0.4
0.41231
0.42426
0.43589
0.44721
0.45826
0.46904
0.47958
0.48990
0.5
0.50990
0.51962
0.52915
0.53852
0.54772
0.55678
·~oB '"
i- ;I
3
2.8868
2.7735
2.6726
2.5820
2.5
2.4254
2,3570
2.2942
2.2361
2.1822
2.1320
2.0851
2.0412
2
1.9612
1.9245
1.8898
1.8570
1.8257
1.7961
1.7678
TABLE 2 cont'd: Monogenic nullizygous risk
Go.0.33
0.34
0.35
0.36
0.37
0.384
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
q
0.67082446
0.6782310
0.65579
0.60000
0.67082711
0.672110.62450
0.6328010.64031
0.734807
0.655741
0.74866332
0.75498
0.76158
0.7681157
0.7469282
0.78102
0.78740.714 4
.72111
.72801
. 3485
0.79373
0.8
0.80623
0.81240
GRR (1 parent)
1.7408
1.6903
1.664744
1.6440
1.4286222
1.6013
1.581140031.5617
1.5430
1.5250
1.5076
1.5
1.4907
1.4744
1.4586
1.4434
1.4286
1.4142
1.4003
1.3868
1.3736
1.3608
1.3484
1.3363
1.3245
1.3131
1.3019
1.2910
1.2804
1.2700
1.2599
1.25
1.2403
1.2309
TABLE 2 cont'd: Monogenic nullizygous risk
GRR (1 parent)
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
0.81854
0.82462
0.83066
0.83666
0.84261
0.84853
0.85440
0.86023
0.86603
0.87178
0.87750
0.88318
0.88882
0.89443
0.9
0.90554
0.91104
0.91652
0.92195
0.92736
0.93274
0.93808
0.94340
0.94868
0.95394
0.95917
0.96437
0.96954
0.97468
0.97980
0.98489
0.98995
0.99499
1
Go q
1.2217
1.2127
1.2039
1.1952
1.1868
1.1785
1.1704
1.1625
1.1547
1.1471
1.1396
1.1323
1.1251
1.1180
1.1111
1.1043
1.0976
1.0911
1.0847
1.0783
1.0721
1.0660
1.0600
1.0541
1.0483
1.0426
1.0370
1.0314
1.0260
1.0206
1.0153
1.0102
1.0050
1
TABLE 3: Multigenic heterozygous risk, m= 2 (Go < 0.75)
Go q 1-q GRR
0.01 0.00251 0.99749 50.2506
0.02 0.00505 0.99495 25.2513
0.03 0.00762 0.99238 16.9186
0.04 0.01021 0.98979 12.7526
0.05 0.01282 0.98718 10.2532
0.06 0.01547 0.98453 8.5872
0.07 0.01815 0.98185 7.3974
0.08 0.02085 0.97915 6.5052
0.09 0.02359 0.97641 5.8114
0.1 0.02635 0.97365 5.2566
0.11 0.02915 0.97085 4.8027
0.12 0.03198 0.96802 4.4247
0.13 0.03485 0.96515 4.1049
0.14 0.03774 0.96226 3.8309
0.15 0.04068 0.95932 3.5935
0.16 0.04365 0.95635 3.3859
0.17 0.04666 0.95334 3.2028
0.18 0.04970 0.95030 3.0402
0.1827 0.05052 0.94948 3.0000
0.19 0.05279 0.94721 2.8947
0.2 0.05591 0.94409 2.7639
0.21 0.05908 0.94092 2.6457
0.22 0.06229 0.93771 2.5382
0.2238 0.06352 0.93648 2.5000
0.23 0.06555 0.93445 2.4402
0.24 0.06885 0.93115 2.3505
0.25 0.07220 0.92780 2.2679
0.26 0.07560 0.92440 2.1919
0.27 0.07905 0.92095 2.1215
0.28 0.08255 0.91745 2.0562
0.2892 0.08583 0.91417 2.0000
0.29 0.08611 0.91389 1.9955
0.3 0.08972 0.91028 1.9389
0.31 0.09339 0.90661 1.8860
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TABLE 3 cont'd: Multigenic heterozygous risk, m = 2 (Go < 0.75)
q
0.10092
0.10478
0.10870
0.11270
0.11677
0.12092
0.12515
0.12946
0.13386
0.13422
0.13835
0.14294
0.14763
0.15242
0.15733
0.16235
0.16750
0.17278
0.17820
0.18377
0.18950
0.19540
0.20148
0.20775
0.21423
0.22094
0.22790
0.23513
0.24265
0.25050
0.25871
0.26732
0.27639
0.28598
0.29617
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.4108
0.42
0.43
0.44
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
1-q
0.89908
0.89522
0.89130
0.88730
0.88323
0.87908
0.87485
0.87054
0.86614
0.86578
0.86165
0.85706
0.85237
0.84758
0.84267
0.83765
0.83250
0.82722
0.82180
0.81623
0.81050
0.80460
0.79852
0.79225
0.78577
0.77906
0.77210
0.76487
0.75735
0.74950
0.74129
0.73268
0.72361
0.71402
0.70383
GRR
1.7901
1.7465
1.7054
1.6667
1.6301
1.5955
1.5628
1.5318
1.5023
1.5000
1.4743
1.4477
1.4224
1.3982
1.3752
1.3532
1.3322
1.3121
1.2929
1.2745
1.2569
1.2400
1.2239
1.2083
1.1935
1.1792
1.1655
1.1523
1.1396
1.1275
1.1158
1.1045
1.0938
1.0834
1.0734
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TABLE 3 cont'd: Multigenic heterozygous risk, m = 2 (G o • 0.75)
Go q 1-q GRR
0.67 0.30705 0.69295 1.0638
0.68 0.31877 0.68123 1.0546
0.69 0.33151 0.66849 1.0458
0.7 0.34553 0.65447 1.0373
0.71 0.36123 0.63877 1.0292
0.72 0.37927 0.62073 1.0214
0.73 0.40097 0.59903 1.0140
0.74 0.42964 0.57036 1.0068
0.75 0.5 0.5 1
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TABLE 4: Multigenic heterozygous risk, m = 3 (Go ! 0.875)
Go q 1-q GRR
0.01 0.00168 0.99832 50.3339
0.02 0.00337 0.99663 25.3345
0.03 0.00508 0.99492 17.0017
0.04 0.00680 0.99320 12.8356
0.05 0.00855 0.99145 10.3362
0.06 0.01031 0.98969 8.6701
0.07 0.01210 0.98790 7.4802
0.08 0.01390 0.98610 6.5879
0.09 0.01572 0.98428 5.8941
0.1 0.01756 0.98244 5.3392
0.11 0.01943 0.98057 4.8852
0.12 0.02131 0.97869 4.5070
0.13 0.02322 0.97678 4.1872
0.14 0.02515 0.97485 3.9131
0.15 0.02710 0.97290 3.6756
0.16 0.02908 0.97092 3.4679
0.17 0.03108 0.96892 3.2847
0.18 0.03310 0.96690 3.1220
0.1883 0.03480 0.96520 3.0000
0.19 0.03515 0.96485 2.9765
0.2 0.03723 0.96277 2.8456
0.21 0.03933 0.96067 2.7272
0.22 0.04146 0.95854 2.6197
0.23 0.04362 0.95638 2.5215
0.2323 0.04412 0.95588 2.5000
0.24 0.04581 0.95419 2.4317
0.25 0.04803 0.95197 2.3490
0.26 0.05028 0.94972 2.2728
0.27 0.05256 0.94744 2.2023
0.28 0.05487 0.94513 2.1369
0.29 0.05722 0.94278 2.0761
0.3 0.05960 0.94040 2.0194
0.3036 0.06046 0.93954 2.0000
0.31 0.06202 0.93798 1.9664
0.32 0.06447 0.93553 1.9167
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TABLE 4 cont'd: Multigenic heterozygous risk, m = 3 (G o <:0.875)
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.4403
0.89958
0.89644
0.89323
0.88996
0.88662
0.88321
0.87972
0.87615
0.87249
0.86874
0.86490
0.86096
0.85692
0.85277
0.84849
0.84410
0.83957
0.83490
0.83008
0.82510
0.81995
0.81461
q
0.06697
0.06950
0.07208
0.07469
0.07735
0.08006
0.08281
0.08561
0.08847
0.09137
0.09433
0.09735
0.09743
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
1-q
0.93303
0.93050
0.92792
0.92531
0.92265
0.91994
0.91719
0.91439
0.91153
0.90863
0.90567
0.90265
0.90257
0.10042
0.10356
0.10677
0.11004
0.11338
0.11679
0.12028
0.12385
0.12751
0.13126
0.13510
0.13904
0.14308
0.14723
0.15151
0.15590
0.16043
0.16510
0.16992
0.17490
0.18005
0.18539
GRR
1.8702
1.8264
1.7852
1.7463
1.7096
1.6749
1.6420
1.6108
1.5812
1.5530
1.5262
1.5007
1.5000
1.4763
1.4531
1.4309
1.4097
1.3895
1.3700
1.3514
1.3336
1.3165
1.3001
1.2843
1.2692
1.2546
1.2407
1.2272
1.2143
1.2018
1.1898
1.1783
1.1671
1.1564
1.1461
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TABLE 4 cont'd: Multigenic heterozygous risk, m = 3 (Go < 0.875)
GRR
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.875
0.19094
0.19669
0.20269
0.20894
0.21547
0.22232
0.22951
0.23708
0.24509
0.25358
0.26263
0.27231
0.28275
0.29408
0.30649
0.32025
0.33574
0.35357
0.37484
0.40189
0.44264
0.5
1-q
0.80906
0.80331
0.79731
0.79106
0.78453
0.77768
0.77049
0.76292
0.75491
0.74642
0.73737
0.72769
0.71725
0.70592
0.69351
0.67975
0.66426
0.64643
0.62516
0.59811
0.55736
0.5
1.1362
1.1266
1.1174
1.1085
1.0999
1.0917
1.0837
1.0761
1.0688
1.0617
1.0549
1.0484
1.0422
1.0363
1.0306
1.0251
1.0200
1.0150
1.0104
1.0060
1.0019
1
105
Go q
TABLE 5: Multigenic heterozygous risk, m= 4 (Go < 0.9375)
G o  q 1-_q GRR
0.01 0.00126 0.99874 50.3755
0.02 0.00253 0.99747 25.3759
0.03 0.00381 0.99619 17.0431
0.04 0.00510 0.99490 12.8769
0.05 0.00641 0.99359 10.3774
0.06 0.00773 0.99227 8.7112
0.07 0.00907 0.99093 7.5212
0.08 0.01042 0.98958 6.6289
0.09 0.01179 0.98821 5.9349
0.1 0.01317 0.98683 5.3799
0.11 0.01457 0.98543 4.9259
0.12 0.01598 0.98402 4.5476
0.13 0.01741 0.98259 4.2276
0.14 0.01886 0.98114 3.9534
0.15 0.02032 0.97968 3.7158
0.16 0.02180 0.97820 3.5081
0.17 0.02330 0.97670 3.3248
0.18 0.02482 0.97518 3.1619
0.19 0.02635 0.97365 3.0163
0.1912 0.02654 0.97346 3.0000
0.2 0.02791 0.97209 2.8853
0.21 0.02948 0.97052 2.7668
0.22 0.03108 0.96892 2.6591
0.23 0.03270 0.96730 2.5609
0.2367 0.03379 0.96621 2.5000
0.24 0.03433 0.96567 2.4709
0.25 0.03599 0.96401 2.3881
0.26 0.03768 0.96232 2.3118
0.27 0.03938 0.96062 2.2412
0.28 0.04111 0.95889 2.1757
0.29 0.04287 0.95713 2.1147
0.3 0.04465 0.95535 2.0579
0.31 0.04645 0.95355 2.0047
0.3109 0.04662 0.95338 2.0000
0.32 0.04829 0.95171 1.9550
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TABLE 5 cont'd: Multigenic heterozygous risk, m = 4 (Go 50.9375)
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.4553
0.07737
0.07974
0.08216
0.08463
0.08715
0.08972
0.09235
0.09504
0.09779
0.10060
0.10349
0.10644
0.10947
0.11258
0.11577
0.11905
0.12242
0.12589
0.12946
0.13315
0.13695
0.05015
0.05204
0.05396
0.05591
0.05790
0.05991
0.06196
0.06405
0.06617
0.06833
0.07052
0.07276
0.07504
0.07628
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
1-q
0.94985
0.94796
0.94604
0.94409
0.94210
0.94009
0.93804
0.93595
0.93383
0.93167
0.92948
0.92724
0.92496
0.92372
0.92263
0.92026
0.91784
0.91537
0.91285
0.91028
0.90765
0.90496
0.90221
0.89940
0.89651
0.89356
0.89053
0.88742
0.88423
0.88095
0.87758
0.87411
0.87054
0.86685
0.86305
GRR
1.9083
1.8643
1.8230
1.7840
1.7471
1.7122
1.6792
1.6478
1.6181
1.5897
1.5628
1.5371
1.5126
1.5000
1.4892
1.4668
1.4455
1.4250
1.4054
1.3866
1.3686
1.3513
1.3347
1.3187
1.3034
1.2886
1.2744
1.2607
1.2475
1.2348
1.2226
1.2108
1.1994
1.1884
1.1778
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TABLE 5 cont'd: Multigenic heterozygous risk, m = 4 (Go 0.9375)
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.9375
0.14088
0.14495
0.14916
0.15353
0.15807
0.16279
0.16770
0.17283
0.17820
0.18383
0.18974
0.19597
0.20255
0.20953
0.21696
0.22490
0.23343
0.24265
0.25268
0.26368
0.27588
0.28956
0.30519
0.32345
0.34553
0.37385
0.41524
0.5
0.85912
0.85505
0.85084
0.84647
0.84193
0.83721
0.83230
0.82717
0.82180
0.81617
0.81026
0.80403
0.79745
0.79047
0.78304
0.77510
0.76657
0.75735
0.74732
0.73632
0.72412
0.71044
0.69481
0.67655
0.65447
0.62615
0.58476
0.5
GRR
1.1676
1.1577
1.1482
1.1390
1.1302
1.1216
1.1133
1.1053
1.0976
1.0902
1.0830
1.0761
1.0695
1.0631
1.0569
1.0510
1.0453
1.0399
1.0347
1.0297
1.0250
1.0205
1.0163
1.0123
1.0086
1.0052
1.0021
1
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Go q 1-q
TABLE 6: Multigenic heterozygous risk, m = 5 (Go < 0.96875)
Go  q 1-q GRR
0.01 0.00101 0.99899 50.4004
0.02 0.00202 0.99798 25.4008
0.03 0.00305 0.99695 17.0679
0.04 0.00408 0.99592 12.9016
0.05 0.00513 0.99487 10.4020
0.06 0.00619 0.99381 8.7358
0.07 0.00726 0.99274 7.5457
0.08 0.00834 0.99166 6.6533
0.09 0.00943 0.99057 5.9593
0.1 0.01054 0.98946 5.4042
0.11 0.01165 0.98835 4.9501
0.12 0.01278 0.98722 4.5717
0.13 0.01393 0.98607 4.2516
0.14 0.01508 0.98492 3.9774
0.15 0.01625 0.98375 3.7397
0.16 0.01744 0.98256 3.5318
0.17 0.01864 0.98136 3.3485
0.18 0.01985 0.98015 3.1856
0.19 0.02108 0.97892 3.0398
0.1929 0.02144 0.97856 3.0000
0.2 0.02232 0.97768 2.9087
0.21 0.02358 0.97642 2.7902
0.22 0.02486 0.97514 2.6824
0.23 0.02615 0.97385 2.5841
0.2393 0.02737 0.97263 2.5000
0.24 0.02746 0.97254 2.4940
0.25 0.02878 0.97122 2.4112
0.26 0.03013 0.96987 2.3347
0.27 0.03149 0.96851 2.2640
0.28 0.03288 0.96712 2.1984
0.29 0.03428 0.96572 2.1373
0.3 0.03570 0.96430 2.0804
0.31 0.03714 0.96286 2.0272
0.3154 0.03793 0.96207 2.0000
0.32 0.03861 0.96139 1.9773
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TABLE 6 cont'd: Multigenic heterozygous risk, m = 5 (Go < 0.96875)
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.46
0.4644
0.06368
0.06560
0.06756
0.06956
0.07161
0.07369
0.07583
0.07801
0.08024
0.08252
0.08486
0.08725
0.08971
0.09223
0.09482
0.09747
0.10020
0.10302
0.10591
0.10889
q
0.04009
0.04160
0.04314
0.04469
0.04627
0.04788
0.04952
0.05118
0.05287
0.05459
0.05634
0.05812
0.05994
0.06179
0.06261
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
1-q
0.95991
0.95840
0.95686
0.95531
0.95373
0.95212
0.95048
0.94882
0.94713
0.94541
0.94366
0.94188
0.94006
0.93821
0.93739
0.93632
0.93440
0.93244
0.93044
0.92839
0.92631
0.92417
0.92199
0.91976
0.91748
0.91514
0.91275
0.91029
0.90777
0.90518
0.90253
0.89980
0.89698
0.89409
0.89111
GRR
1.9305
1.8865
1.8450
1.8059
1.7689
1.7339
1.7008
1.6693
1.6394
1.6110
1.5839
1.5581
1.5335
1.5100
1.5000
1.4875
1.4660
1.4454
1.4257
1.4067
1.3886
1.3711
1.3544
1.3383
1.3228
1.3078
1.2935
1.2796
1.2663
1.2534
1.2410
1.2290
1.2175
1.2063
1.1955
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TABLE 6 cont'd: Multigenic heterozygous risk, m = 5 (Go < 0.96875)
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.96875
0.11197
0.11515
0.11844
0.12184
0.12537
0.12903
0.13284
0.13680
0.14093
0.14525
0.14977
0.15451
0.15950
0.16475
0.17032
0.17622
0.18251
0.18924
0.19647
0.20430
0.21282
0.22216
0.23251
0.24411
0.25731
0.27260
0.29082
0.31335
0.34303
0.38752
0.5
0.88803
0.88485
0.88156
0.87816
0.87463
0.87097
0.86716
0.86320
0.85907
0.85475
0.85023
0.84549
0.84050
0.83525
0.82968
0.82378
0.81749
0.81076
0.80353
0.79570
0.78718
0.77784
0.76749
0.75589
0.74269
0.72740
0.70918
0.68665
0.65697
0.61248
0.5
GRR
1.1851
1.1751
1.1653
1.1559
1.1469
1.1381
1.1296
1.1214
1.1134
1.1057
1.0983
1.0911
1.0842
1.0775
1.0711
1.0649
1.0589
1.0531
1.0475
1.0422
1.0371
1.0322
1.0275
1.0231
1.0189
1.0149
1.0112
1.0078
1.0047
1.0020
1
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TABLE 7: Multigenic nullizygous risk, m = 2
Go
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.0760
0.08
0.09
0.1
0.11
0.1157
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.1955
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.32
q
0.07080
0.10025
0.12294
0.14214
0.15912
0.17454
0.18877
0.19683
0.20207
0.21462
0.22653
0.23791
0.24420
0.24883
0.25935
0.26951
0.27937
0.28894
0.29826
0.30735
0.31623
0.32104
0.32492
0.33344
0.34180
0.35001
0.35808
0.36603
0.37385
0.38158
0.38919
0.39672
0.40415
0.41151.
0.41878
GRR
7.5457
5.4648
4.5399
3.9868
3.6083
3.3281
3.1097
3.0000
2.9332
2.7866
2.6622
2.5550
2.5000
2.4612
2.3782
2.3041
2.2374
2.1769
2.1217
2.0710
2.0242
2.0000
1.9809
1.9407
1.9031
1.8680
1.8349
1.8038
1.7745
1.7467
1.7204
1.6954
1.6716
1.6489
1.6272
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TABLE 7 cont'd: Multigenic nullizygous risk, m = 2
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.3891
0.39
0.47
0.41
0.42
0.43
0.44
0.45
0.46
0.47
0.48
0.49
0.57
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.65
0.61
0.62
0.63
0.64
0.65
0.66
q
0.42599
0.43312
0.44020
0.44721
0.45417
0.46108
0.46735
0.46795
0.47477
0.48154
0.48829
0.49499
0.50167
0.50831
0.51493
0.52153
0.52810
0.53466
0.54120
0.54772
0.55424
0.56074
0.56725
0.57374
0.58024
0.58673
0.59323
0.59974
0.60625
0.61278
0.61932
0.62588
0.63246
0.63906
0.64568
GRR
1.6065
1.5867
1.5482976
1.5494
1.5318
1.5149
1.5000
1.4986
1.4829
1.4677
1.4531
1.4389
1.4252
1.4119
1.3990
1.3865
1.3744
1.3626
1.3512
1.3400
1.3292
1.3186
1.3083
1.2983
1.2885
1.2790
1.2696
1.2605
1.2516
1.2429
1.2344
1.2261
1.2179
1.2099
1.2021
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TABLE 7 cont'd: Multigenic nullizygous risk, m = 2
Go
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
0.65234
0.65903
0.66575
0.67252
0.67933
0.68618
0.69310
0.70007
0.70711
0.71421
0.72140
0.72867
0.73603
0.74350
0.75107
0.75877
0.76661
0.77460
0.78275
0.79110
0.79965
0.80845
0.81752
0.82691
0.83666
0.84685
0.85757
0.86894
0.88113
0.89443
0.90928
0.92660
0.94868
1
GRR
1.1945
1.1869
1.1796
1.1723
1.1652
1.1583
1.1514
1.1447
1.1381
1.1316
1.1252
1.1189
1.1127
1.1066
1.1006
1.0947
1.0889
1.0831
1.0775
1.0719
1.0664
1.0610
1.0556
1.0503
1.0451
1.0399
1.0347
1.0297
1.0247
1.0197
1.0147
1.0098
1.0049
1
114
q
TABLE 8: Multigenic nullizygous risk, m = 3
Go
0.01
0.02
0.03
0.04
0.05
q __
0.05783
0.08192
0.10051
0.11625
0.13020
0.14042
0.14288
0.15460
0.16556
0.17592
0.17708
0.18577
0.19519
0.20425
0.21298
0.22143
0.22963
0.23762
0.23893
0.24540
0.25300
0.26044
0.26774
0.27489
0.28193
0.28885
0.29567
0.30239
0.30902
0.31558
0.32205
0.32846
0.33481
0.34109
0.34732
GRR
6.4123
4.7103
3.9529
3.4995
3.1888
0.0580
0.06
0.07
0.08
0.09
0.0912
0.1
0.11
0.12
0.13
0.14
0.15
0.16
0.1617
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.32
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3.0000
2.9586
2.7789
2.6335
2.5126
2.5000
2.4100
2.3214
2.2438
2.1751
2.1136
2.0582
2.0080
2.0000
1.9620
1.9198
1.8809
1.8448
1.8111
1.7797
1.7503
1.7226
1.6965
1.6719
1.6486
1.6264
1.6053
1.5853
1.5661
1.5478
TABLE 8 cont'd: Multigenic nullizygous risk, m = 3
Go
0.33
0.34
0.3483
GRR
1.5303
1.5135
1.5000
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
116
q
0.35351
0.35964
0.36471
0.36573
0.37179
0.37781
0.38379
0.38975
0.39569
0.40160
0.40749
0.41336
0.41922
0.42506
0.43090
0.43673
0.44255
0.44838
0.45420
0.46003
0.46586
0.47170
0.47755
0.48342
0.48929
0.49519
0.50111
0.50705
0.51302
0.51902
0.52506
0.53113
0.53723
0.54339
0.54959
1.4973
1.4818
1.4669
1.4525
1.4386
1.4253
1.4123
1.3998
1.3877
1.3759
1.3646
1.3535
1.3428
1.3324
1.3222
1.3123
1.3027
1.2934
1.2842
1.2753
1.2666
1.2581
1.2498
1.2417
1.2338
1.2260
1.2185
1.2110
1.2037
1.1966
1.1896
1.1827
TABLE 8 cont'd: Multigenic nullizygous risk, m = 3
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
0.55584
0.56215
0.56852
0.57495
0.58145
0.58804
0.59470
0.60146
0.60831
0.61527
0.62234
0.62954
0.63687
0.64436
0.65200
0.65983
0.66786
0.67610
0.68460
0.69336
0.70244
0.71187
0.72170
0.73201
0.74287
0.75440
0.76673
0.78007
0.79473
0.81117
0.83023
0.85356
0.88575
1
GRR
1.1760
1.1693
1.1628
1.1565
1.1502
1.1440
1.1379
1.1320
1.1261
1.1203
1.1146
1.1090
1.1034
1.0980
1.0926
1.0873
1.0820
1.0768
1.0717
1.0667
1.0617
1.0567
1.0518
1.0470
1.0422
1.0374
1.0327
1.0280
1.0233
1.0187
1.0140
1.0094
1.0047
1
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TABLE 9: Multigenic nullizygous risk, m = 4
Go
0.01
0.02
0.03
0.04
0.0470
0.05
0.06
0.07
0.0754
0.08
0.09
0.1
0.11
0.12
0.13
0.1383
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.3165
0.32
q
0.05009
0.07098
0.08710
0.10077
0.10933
0.11288
0.12389
0.13409
0.13927
0.14363
0.15265
0.16123
0.16945
0.17735
0.18498
0.19109
0.19236
0.19954
0.20652
0.21334
0.22000
0.22653
0.23293
0.23922
0.24541
0.25150
0.25750
0.26343
0.26928
0.27507
0.28079
0.28646
0.29208
0.29765
0.30123
0.30317
GRR
5.7227
4.2474
3.5905
3.1970
3.0000
2.9272
2.7270
2.5708
2.5000
2.4443
2.3391
2.2496
2.1723
2.1047
2.0447
2.0000
1.9910
1.9426
1.8987
1.8585
1.8215
1.7874
1.7557
1.7262
1.6986
1.6728
1.6485
1.6255
1.6038
1.5833
1.5637
1.5452
1.5275
1.5105
1.5000
1.4944
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TABLE 9 cont'd: Multigenic nullizygous risk, m = 4
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
0.30866
0.31411
0.31953
0.32492
0.33028
0.33562
0.34095
0.34625
0.35154
0.35681
0.36208
0.36734
0.37259
0.37785
0.38310
0.38835
0.39361
0.39888
0.40415
0.40944
0.41474
0.42006
0.42540
0.43076
0.43614
0.44155
0.44700
0.45247
0.45798
0.46353
0.46913
0.47477
0.48046
0.48620
GRRGo
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q
1.4789
1.4640
1.4497
1.4360
1.4227
1.4100
1.3977
1.3858
1.3743
1.3632
1.3524
1.3419
1.3318
1.3219
1.3123
1.3030
1.2940
1.2851
1.2765
1.2682
1.2600
1.2520
1.2442
1.2366
1.2291
1.2218
1.2147
1.2077
1.2008
1.1941
1.1875
1.1811
1.1747
1.1685
--- ------~
TABLE 9 cont'd: Multigenic nullizygous risk, m = 4
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
Go GRR
q
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q |
0.49201
0.49787
0.50381
0.50982
0.51591
0.52209
0.52835
0.53472
0.54120
0.54779
0.55451
0.56137
0.56838
0.57555
0.58291
0.59046
0.59824
0.60625
0.61455
0.62314
0.63209
0.64143
0.65123
0.66156
0.67252
0.68423
0.69687
0.71069
0.72604
0.74350
0.76408
0.78990
0.82691
1
1.1624
1.1564
1.1505
1.1447
1.1390
1.1334
1.1279
1.1224
1.1171
1.1118
1.1065
1.1014
1.0963
1.0913
1.0864
1.0815
1.0767
1.0719
1.0672
1.0625
1.0579
1.0533
1.0487
1.0442
1.0398
1.0353
1.0309
1.0265
1.0221
1.0178
1.0134
1.0090
1.0046
1
----- ~-
TABLE 10: Multigenic nullizygous risk, m = 5
Go
0.01
0.02
0.03
0.0395
0.04
0.05
0.06
0.0643
0.07
0.08
0.09
0.1
0.11
0.12
0.1209
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.2906
0.3
0.31
0.32
q
0.04481
0.06350
0.07793
0.08958
0.09017
0.10103
0.11090
0.11490
0.12004
0.12860
0.13669
0.14440
0.15178
0.15888
0.15954
0.16574
0.17238
0.17883
0.18512
0.19126
0.19726
0.20315
0.20892
0.21459
0.22018
0.22568
0.23110
0.23646
0.24175
0.24699
0.25217
0.25730
0.25762
0.26239
0.26744
0.27246
GRR
5.2460
3.9258
3.3376
3.0000
2.9851
2.7434
2.5640
2.5000
2.4239
2.3104
2.2159
2.1356
2.0662
2.0054
2.0000
1.9515
1.9032
1.8597
1.8201
1.7839
1.7506
1.7198
1.6913
1.6647
1.6398
1.6164
1.5944
1.5737
1.5541
1.5355
1.5178
1.5010
1.5000
1.4850
1.4697
1.4550
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TABLE 10 cont'd: Multigenic nullizygous risk, m = 5
Go
Go GRR
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
122
q
0.27744
0.28239
0.28731
0.29222
0.29710
0.30196
0.30681
0.31164
0.31646
0.32128
0.32609
0.33090
0.33570
0.34051
0.34532
0.35013
0.35496
0.35979
0.36464
0.36950
0.37437
0.37927
0.38419
0.38913
0.39410
0.39910
0.40413
0.40920
0.41431
0.41946
0.42465
0.42989
0.43519
0.44054
1.4409
1.4275
1.4145
1.4020
1.3900
1.3784
1.3672
1.3564
1.3459
1.3358
1.3260
1.3164
1.3072
1.2982
1.2894
1.2809
1.2727
1.2646
1.2567
1.2491
1.2416
1.2342
1.2271
1.2201
1.2133
1.2066
1.2000
1.1936
1.1873
1.1811
1.1751
1.1691
1.1633
1.1575
TABLE 10 cont'd: Multigenic nullizygous risk, m = 5
q
Go
GRR
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q0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
0.44595
0.45143
0.45697
0.46260
0.46830
0.47410
0.47999
0.48598
0.49208
0.49830
0.50465
0.51115
0.51780
0.52461
0.53162
0.53883
0.54626
0.55395
0.56191
0.57019
0.57884
0.58789
0.59741
0.60749
0.61822
0.62975
0.64225
0.65599
0.67136
0.68898
0.70998
0.73668
0.77582
1
1.1519
1.1464
1.1409
1.1356
1.1303
1.1251
1.1200
1.1149
1.1099
1.1050
1.1002
1.0954
1.0907
1.0860
1.0814
1.0769
1.0724
1.0679
1.0635
1.0591
1.0548
1.0505
1.0462
1.0420
1.0378
1.0336
1.0294
1.0253
1.0211
1.0170
1.0128
1.0087
1.0044
1
TABLE 11: Polygenic heterozygous risk, n= 2 (GO <0.25)
Go q 1-q GRR
0.01 0.05279 0.94721 25
0.02 0.07657 0.92343 12.5
0.03 0.09578 0.90422 8.3333
0.04 0.11270 0.88730 6.25
0.05 0.12825 0.87175 5
0.06 0.14289 0.85711 4.1667
0.07 0.15691 0.84309 3.5714
0.08 0.17049 0.82951 3.125
0.0833 0.17494 0.82506 3
0.09 0.18377 0.81623 2.7778
0.1 0.19687 0.80313 2.5
0.11 0.20988 0.79012 2.2727
0.12 0.22288 0.77712 2.0833
0.125 0.22940 0.77060 2
0.13 0.23595 0.76405 1.9231
0.14 0.24917 0.75083 1.7857
0.15 0.26262 0.73738 1.6667
0.16 0.27639 0.72361 1.5625
0.1667 0.28582 0.71418 1.5
0.17 0.29061 0.70939 1.4706
0.18 0.30540 0.69460 1.3889
0.19 0.32096 0.67904 1.3158
0.2 0.33754 0.66246 1.25
0.21 0.35553 0.64447 1.1905
0.22 0.37558 0.62442 1.1364
0.23 0.39896 0.60104 1.0870
0.24 0.42893 0.57107 1.0417
0.25 0.5 0.5 1
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TABLE 12: Polygenic nullizygous risk, n = 2-5
GRR (1 parent)
10
7.0711
5.7735
5
4.4721
4.0825
3.7796
3.5355
3.3333
3.1623
3.0151
Go
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0.11
0.1111
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.32
125
p (n = 2)
0.68377
0.62394
0.58382
0.55279
0.52713
0.50508
0.48563
0.46817
0.45228
0.43766
0.42410
0.42265
0.41143
0.39954
0.38831
0.37767
0.36754
0.35789
0.34864
0.33978
0.33126
0.32305
0.31513
0.30748
0.30007
0.29289
0.28593
0.27916
0.27257
0.26616
0.25992
0.25383
0.24788
p (n = 3)
0.53584
0.47900
0.44257
0.41520
0.39304
0.37431
0.35803
0.34358
0.33057
0.31871
0.30780
0.30664
0.29769
0.28826
0.27941
0.27108
0.26319
0.25571
0.24859
0.24179
0.23528
0.22903
0.22303
0.21725
021168
0.20630
0.20109
0.19605
0.19117
0.18642
0.18181
0.17733
0.17296
3
2.8868
2.7735
2.6726
2.5820
2.5
2.4254
2.3570
2.2942
2.2361
2.1822
2.1320
2.0851
2.0412
2
1.9612
1.9245
1.8898
1.8570
1.8257
1.7961
1.7678
p(n = 4)
0.43766
0.38676
0.35488
0.33126
0.31234
0.29649
0.28280
0.27073
0.25992
0.25011
0.24112
0.24016
0.23282
0.22510
0.21789
0.21112
0.20473
0.19868
0.19293
0.18746
0.18223
0.17723
0.17243
0.16782
0.16338
0.15910
0.15497
0.15098
0.14711
0.14336
0.13972
0.13619
0.13275
p (n = 5)
0.36904
0.32376
0.29577
0.27522
0.25887
0.24523
0.23350
0.22320
0.21400
0.20567
0.19806
0.19726
0.19106
0.18456
0.17849
0.17280
0.16745
0.16238
0.15758
0.15302
0.14866
0.14450
0.14051
0.13668
0.13300
0.12945
0.12603
0.12272
0.11953
0.11643
0.11343
0.11052
0.10769
-i
TABLE 12 cont'd: Polygenic nullizygous risk, n = 2-5
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.4444
1.4907
1.4744
1.4586
1.4434
1.4286
1.4142
1.4003
1.3868
1.3736
1.3608
1.3484
1.3363
1.3245
1.3131
1.3019
1.2910
1.2804
1.2700
1.2599
1.2500
1.2403
1.2309
126
p(n = 2)
0.24207
0.23639
0.23084
0.22540
0.22008
0.21486
0.20975
0.20473
0.19980
0.19497
0.19022
0.18555
0.18350
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
p(n = 3)
0.16871
0.16456
0.16052
0.15657
0.15271
0.14893
0.14524
0.14163
0.13809
0.13462
0.13122
0.12788
0.12642
0.18096
0.17645
0.17201
0.16764
0.16334
0.15910
0.15493
0.15082
0.14676
0.14277
0.13883
0.13494
0.13110
0.12732
0.12358
0.11989
0.11624
0.11264
0.10909
0.10557
0.10210
0.09867
p (n = 4)
0.12941
0.12615
0.12298
0.11989
0.11687
0.11392
0.11104
0.10822
0.10546
0.10277
0.10012
0.09753
0.09640
0.12461
0.12140
0.11824
0.11514
0.11210
0.10910
0.10616
0.10326
0.10041
0.09760
0.09484
0.09211
0.08943
0.08679
0.08418
0.08161
0.07908
0.07658
0.07412
0.07168
0.06928
0.06691
p (n = 5)
0.10494
0.10227
0.09966
0.09712
0.09464
0.09222
0.08986
0.08756
0.08530
0.08309
0.08093
0.07882
0.07789
0.09499
0.09250
0.09006
0.08766
0.08531
0.08300
0.08072
0.07849
0.07629
0.07413
0.07201
0.06991
0.06785
0.06582
0.06383
0.06186
0.05992
0.05800
0.05612
0.05426
0.05242
0.05061
GRR (1 parent)
1.7408
1.7150
1.6903
1.6667
1.6440
1.6222
1.6013
1.5811
1.5617
1.5430
1.5250
1.5076
1.5
0.07675
0.07471
0.07272
0.07077
0.06885
0.06697
0.06512
0.06330
0.06151
0.05976
0.05803
0.05633
0.05466
0.05302
0.05140
0.04980
0.04823
0.04668
0.04515
0.04365
0.04216
0.040700.06691
TABLE 12 cont'd: Polygenic nullizygous risk, n = 2-5
GRR (1 parent)
Go
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Go
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
p (n = 2)
0.09527
0.09191
0.08859
0.08531
0.08206
0.07884
0.07566
0.07251
0.06940
0.06631
0.06325
0.06023
0.05723
0.05426
0.05132
0.04840
0.04551
0.04265
0.03982
0.03700
0.03422
0.03145
0.02871
0.02600
0.02330
0.02063
0.01798
0.01535
0.01274
0.01015
0.00759
0.00504
0.00251
0
p (n = 3)
0.06457
0.06225
0.05997
0.05771
0.05548
0.05328
0.05110
0.04895
0.04682
0.04471
0.04263
0.04056
0.03853
0.03651
0.03451
0.03253
0.03058
0.02864
0.02672
0.02482
0.02294
0.02108
0.01923
0.01741
0.01560
0.01380
0.01202
0.01026
0.00851
0.00678
0.00506
0.00336
0.00167
0
p (n = 4)
0.04883
0.04706
0.04532
0.04361
0.04191
0.04023
0.03858
0.03694
0.03532
0.03372
0.03214
0.03058
0.02904
0.02751
0.02600
0.02450
0.02302
0.02156
0.02011
0.01868
0.01726
0.01585
0.01446
0.01308
0.01172
0.01037
0.00903
0.00770
0.00639
0.00509
0.00380
0.00252
0.00126
0
p (n = 5)
0.03926
0.03783
0.03643
0.03504
0.03367
0.03232
0.03098
0.02966
0.02836
0.02707
0.02580
0.02454
0.02330
0.02207
0.02085
0.01965
0.01846
0.01728
0.01612
0.01497
0.01383
0.01270
0.01159
0.01048
0.00939
0.00830
0.00723
0.00617
0.00512
0.00407
0.00304
0.00202
0.00100
0
1.2217
1.2127
1.2039
1.1952
1.1868
1.1785
1.1704
1.1625
1.1547
1.1471
1.1396
1.1323
1.1251
1.1180
1.1111
1.1043
1.0976
1.0911
1.0847
1.0783
1.0721
1.0660
1.0600
1.0541
1.0483
1.0426
1.0370
1.0314
1.0260
1.0206
1.0153
1.0102
1.0050
1
TABLE 13: Polygenic nullizygous risk, n = 10-25
GRR (1 parent)
10
7.0711
5.7735
5
4.4721
4.0825
3.7796
3.5355
3.3333
3.1623
3.0151
Go
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0.11
0.1111
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
0.26
0.27
0.28
0.29
0.3
0.31
0.32
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p (n = 10)
0.20567
0.17766
0.16082
0.14866
0.13911
0.13122
0.12450
0.11864
0.11343
0.10875
0.10449
0.10404
0.10059
0.09698
0.09363
0.09050
0.08756
0.08479
0.08217
0.07968
0.07732
0.07507
0.07291
0.07085
0.06887
0.06697
0.06514
0.06337
0.06167
0.06002
0.05842
0.05688
0.05538
p (n = 15)
0.14230
0.12226
0.11031
0.10174
0.09503
0.08952
0.08483
0.08074
0.07713
0.07388
0.07093
0.07062
0.06824
0.06575
0.06344
0.06128
0.05926
0.05735
0.05556
0.05385
0.05223
0.05069
0.04922
0.04781
0.04646
0.04516
0.04391
0.04271
0.04154
0.04042
0.03934
0.03829
0.03727
p (n = 20)
0.10875
0.09317
0.08393
0.07732
0.07216
0.06792
0.06432
0.06119
0.05842
0.05594
0.05369
0.05345
0.05163
0.04973
0.04796
0.04632
0.04478
0.04333
0.04196
0.04067
0.03944
0.03826
0.03715
0.03608
0.03505
0.03406
0.03312
0.03220
0.03132
0.03047
0.02965
0.02886
0.02808
p (n = 25)
0.08799
0.07526
0.06773
0.06235
0.05816
0.05471
0.05180
0.04926
0.04702
0.04501
0.04319
0.04299
0.04152
0.03998
0.03856
0.03723
0.03599
0.03482
0.03371
0.03267
0.03168
0.03073
0.02983
0.02897
0.02814
0.02735
0.02658
0.02585
0.02514
0.02445
0.02379
0.02315
0.02253
3
2.8868
2.7735
2.6726
2.5820
2.5
2.4254
2.3570
2.2942
2.2361
2.1822
2.1320
2.0851
2.0412
2
1.9612
1.9245
1.8898
1.8570
1.8257
1.7961
1.7678
TABLE 13 cont'd: Polygenic nullizygous risk, n = 10-25
Go
0.33
0.34
0.35
0.36
0.37
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.4444
1.4907
1.4744
1.4586
1.4434
1.4286
1.4142
1.4003
1.3868
1.3736
1.3608
1.3484
1.3363
1.3245
1.3131
1.3019
1.2910
1.2804
1.2700
1.2599
1.2500
1.2403
1.2309
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p (n = 10)
0.05392
0.05251
0.05114
0.04980
0.04850
0.04723
0.04599
0.04478
0.04360
0.04245
0.04132
0.04022
0.03974
0.45
0.46
0.47
0.48
0.49
0.5
0.51
0.52
0.53
0.54
0.55
0.56
0.57
0.58
0.59
0.6
0.61
0.62
0.63
0.64
0.65
0.66
0.03914
0.03808
0.03705
0.03603
0.03504
0.03406
0.03311
0.03217
0.03125
0.03034
0.02945
0.02857
0.02771
0.02687
0.02604
0.02522
0.02441
0.02362
0.02284
0.02207
0.02131
0.02056
p(n = 15)
0.03628
0.03532
0.03439
0.03348
0.03260
0.03174
0.03090
0.03008
0.02928
0.02850
0.02774
0.02699
0.02667
0.02627
0.02555
0.02485
0.02417
0.02350
0.02284
0.02219
0.02156
0.02094
0.02033
0.01973
0.01914
0.01856
0.01799
0.01743
0.01688
0.01634
0.01581
0.01528
0.01477
0.01426
0.01376
p (n = 20)
0.02734
0.02661
0.02590
0.02522
0.02455
0.02390
0.02327
0.02265
0.02204
0.02145
0.02088
0.02032
0.02007
0.01976
0.01923
0.01870
0.01818
0.01768
0.01718
0.01669
0.01622
0.01575
0.01529
0.01483
0.01439
0.01395
0.01353
0.01310
0.01269
0.01228
0.01188
0.01148
0.01110
0.01071
0.01033
p (n = 25)
0.02193
0.02135
0.02078
0.02023
0.01969
0.01917
0.01866
0.01816
0.01767
0.01720
0.01674
0.01629
0.01609
0.01584
0.01541
0.01499
0.01457
0.01417
0.01377
0.01338
0.01299
0.01262
0.01225
0.01189
0.01153
0.01118
0.01084
0.01050
0.01016
0.00984
0.00952
0.00920
0.00889
0.00858
0.00828
GRR (1 parent)
1.7408
1.7150
1.6903
1.6667
1.6440
1.6222
1.6013
1.5811
1.5617
1.5430
1.5250
1.5076
1.5
TABLE 13 cont'd: Polygenic nullizygous risk, n = 10-25
Go
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
0.77
0.78
0.79
0.8
0.81
0.82
0.83
0.84
0.85
0.86
0.87
0.88
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
p (n = 10)
0.01982
0.01910
0.01838
0.01768
0.01698
0.01629
0.01561
0.01494
0.01428
0.01363
0.01298
0.01235
0.01172
0.01110
0.01048
0.00987
0.00927
0.00868
0.00809
0.00751
0.00694
0.00637
0.00581
0.00525
0.00470
0.00416
0.00362
0.00309
0.00256
0.00204
0.00152
0.00101
0.00050
0
p (n = 15)
0.01326
0.01277
0.01229
0.01182
0.01135
0.01089
0.01044
0.00999
0.00954
0.00911
0.00867
0.00825
0.00783
0.00741
0.00700
0.00659
0.00619
0.00579
0.00540
0.00501
0.00463
0.00425
0.00388
0.00351
0.00314
0.00278
0.00242
0.00206
0.00171
0.00136
0.00101
0.00067
0.00033
0
GRR (1 parent)p (n = 20)
0.00996
0.00960
0.00923
0.00888
0.00853
0.00818
0.00784
0.00750
0.00717
0.00684
0.00651
0.00619
0.00588
0.00556
0.00525
0.00495
0.00465
0.00435
0.00405
0.00376
0.00348
0.00319
0.00291
0.00263
0.00235
0.00208
0.00181
0.00155
0.00128
0.00102
0.00076
0.00050
0.00025
0
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p (n = 25)
0.00798
0.00768
0.00739
0.00711
0.00683
0.00655
0.00627
0.00600
0.00574
0.00547
0.00521
0.00496
0.00470
0.00445
0.00421
0.00396
0.00372
0.00348
0.00325
0.00301
0.00278
0.00255
0.00233
0.00210
0.00188
0.00167
0.00145
0.00124
0.00103
0.00082
0.00061
0.00040
0.00020
0
1.2217
1.2127
1.2039
1.1952
1.1868
1.1785
1.1704
1.1625
1.1547
1.1471
1.1396
1.1323
1.1251
1.1180
1.1111
1.1043
1.0976
1.0911
1.0847
1.0783
1.0721
1.0660
1.0600
1.0541
1.0483
1.0426
1.0370
1.0314
1.0260
1.0206
1.0153
1.0102
1.0050
1
DISCUSSION, CONCLUSIONS, AND SUGGESTIONS FOR FURTHER
RESEARCH
Stipulations
Range of values considered for all common late-onset cancers, independent of modes of
inheritance:
3.0 > GRR > 1.5 (for most late-onset cancers, Table 14)(Hemminki, Rawal et al. 2004)
Go > 0.01 (definition of "common" disease)
q > 0 (mean value 0.03, 99% u.c.1. ~ 0.22, from Morgenthaler & Thilly, 2006)
Range of values considered for CRC, using estimates undergoing refinement by
additional analyses, based on the Swedish Family Cancer Database:
3.0 > GRR > 1.5 (1.77 for rectal cancer, 1.86 for CRC, 2.02 for colon cancer, 2.04 for
colorectal adenocarcinoma, 2.58 for age-matched parents-offspring with colon cancer)
(Hemminki, Rawal et al. 2004; Hemminki, Granstrom et al. 2005)
Go > 0.26 (from Figure 6)
Monogenic heterozygous risk
[Figures 8.1-8.4 and Table 1]
All common late-onset cancers
It is clear from inspection of Table 1 that for risk of a common late onset cancer to be
inherited as a monogenic heterozygous condition, values of GRR must be less than 3.0 if
the fraction of the population at risk is greater than 0.16. Only a few forms of cancer -
skin, prostate, colorectal, breast, and lung (among cigarette smokers) - meet this criterion
for minimum lifetime risk, mLR, which we use an estimate of the minimum value of Go.
Pancreatic cancer, the fifth most deadly form of cancer in the U.S., whose mortality
estimates are essentially identical with incidence estimates, has an mLR for males of only
0.08-0.09. Assuming pro tempore that environmental risks now reach nearly all persons,
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values of GRR for pancreatic cancer would have to lie between 5 and 6, were risk to be
encoded as heterozygosity in a single gene. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk of pancreatic and the less common forms of
cancer is excluded from consideration of genetic risk from monogenic heterozygosity.
Colorectal cancer
Using the assumption E~1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by monogenic heterozygosity. Values
of Go > 0.26 and 1.7 < GRR < 1.9 are found in Table 1. These values correspond to
values of 0.15 < q < 0.17 which is less than the 99% u.c.l. calculated for the values of q
for all non-deleterious gene inactivating mutant fractions in human genes. If, for
instance, were recalculations for CRC to find GRR > 2.0, then this mode of simple
Mendelian inheritance would appear to be excluded.
Monogenic nullizygous risk
[Figures 9.1-9.4 and Table 2]
All common late-onset cancers
It is clear from inspection of Table 2 that for risk of a common late onset cancer to be
inherited as a monogenic nullizygous condition, values of GRR must be less than 2.5 if
the fraction of the population at risk is greater than 0.16. Only a few forms of cancer -
skin, prostate, colorectal, breast, and lung (among cigarette smokers) - meet this criterion
for minimum lifetime risk, mLR, which we use an estimate of the minimum value of Go.
Pancreatic cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, i.e. E~ 1, values of GRR for pancreatic
cancer would have to lie between 3.3 and 3.5, were risk to be encoded as nullizygosity in
a single gene. As the Hemminki group has reported few estimates of GRR for late-onset
cancers higher than 3.0, but has reported a general absence of spousal risk, it appears that
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the less common forms of cancer are excluded from consideration of genetic risk from
monogenic nullizygosity.
Colorectal cancer
Using the assumption E- 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by monogenic nullizygosity. Values of
Go > 0.26 and 1.7 < GRR < 1.9 are found in Table 2. These values correspond, however,
to values of 0.5 < q < 0.6 which is considerably than the 99% u.c.l. calculated for the
values of q for all non-deleterious gene inactivating mutant fractions in human genes. If,
for instance, were recalculations for CRC to find GRR > 2.0 then this mode of simple
Mendelian inheritance would appear to be excluded.
Multigenic heterozygous risk (m=2, each gene contributing equal risk)
[Figures 10.1-10.4 and Table 3]
All common late-onset cancers
It is clear from inspection of Table 3 that for risk of a common late onset cancer to be
inherited as a bigenic heterozygous condition, values of GRR must be less than 3.0 if the
fraction of the population at risk is greater than 0.19. Cancers of the skin, prostate,
colorectum, breast, and lung (among cigarette smokers), meet this criterion for minimum
lifetime risk, mLR, which we use an estimate of the minimum value of Go. Pancreatic
cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 5.8 and 6.5 were risk to be encoded in equal amount as
heterozygosity in each of two separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer are excluded
from consideration of genetic risk from bigenic heterozygosity.
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Colorectal cancer
Using the assumption E-1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by bigenic heterozygosity. Values of
Go > 0.26 and 1.7 < GRR < 2.2 are found in Table 3. These values correspond to values
of 0.07 < q < 0.11 which is less than the 99% u.c.l. calculated for the values of q for all
non-deleterious gene inactivating mutant fractions in human genes. If, for instance,
recalculations for CRC to find GRR > 2.2, then this mode of simple Mendelian
inheritance would appear to be excluded.
Multigenic heterozygous risk (m=3, each gene contributing equal risk)
[Figures 11.1-11.4 and Table 4]
All common late-onset cancers
It is clear from inspection of Table 4 that for risk of a common late onset cancer to be
inherited as a trigenic heterozygous condition, values of GRR must be less than 3.0 if the
fraction of the population at risk is greater than 0.19. Cancers of the skin, prostate,
colorectum, breast, and lung (among cigarette smokers), meet this criterion for minimum
lifetime risk, mLR, which we use an estimate of the minimum value of Go. Pancreatic
cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 5.9 and 6.6 were risk to be encoded in equal amount as
heterozygosity in each of three separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer are excluded
from consideration of genetic risk from trigenic heterozygosity.
Colorectal cancer
Using the assumption E~ 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
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it appears possible that CRC risk can be conferred by trigenic heterozygosity. Values of
Go > 0.26 and 1.7 < GRR < 2.3 are found in Table 4. These values correspond to values
of 0.05 < q < 0.08 which approach the mean values of q of -0.03 for all non-deleterious
gene-inactivating mutant fractions in human genes. If, for instance, recalculations for
CRC to find GRR > 2.3, then this mode of simple Mendelian inheritance would appear to
be excluded.
Multigenic heterozygous risk (m=4, each gene contributing equal risk)
[Figures 12.1-12.4 and Table 5]
All common late-onset cancers
It is clear from inspection of Table 5 that for risk of a common late onset cancer to be
inherited as a tetragenic heterozygous condition, values of GRR must be less than 3.0 if
the fraction of the population at risk is greater than 0.19. Cancers of the skin, prostate,
colorectum, breast, and lung (among cigarette smokers), meet this criterion for minimum
lifetime risk, mLR, which we use an estimate of the minimum value of Go. Pancreatic
cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 5.9 and 6.6 were risk to be encoded in equal amount as
heterozygosity in each of four separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer are excluded
from consideration of genetic risk from tetragenic heterozygosity.
Colorectal cancer
Using the assumption E- 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by tetragenic heterozygosity. Values of
Go > 0.26 and 1.7 < GRR < 2.3 are found in Table 5. These values correspond to values
of 0.04<q<0.06 which approach the mean values of q of -0.03 for all non-deleterious
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gene inactivating mutant fractions in human genes. If, for instance, were recalculations
for CRC to find GRR > 2.3 then this mode of simple Mendelian inheritance would
appear to be excluded.
Multigenic heterozygous risk (m = 5, each gene contributing equal risk)
[Figures 13.1-13.4 and Table 6]
All common late-onset cancers
It is clear from inspection of Table 6 that for risk of a common late onset cancer to be
inherited as a pentagenic heterozygous condition, values of GRR must be less than 3.0 if
the fraction of the population at risk is greater than 0.19. Cancers of the skin, prostate,
colorectum, breast, and lung (among cigarette smokers), meet this criterion for minimum
lifetime risk, mLR, which we use an estimate of the minimum value of Go. Pancreatic
cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 5.9 and 6.7 were risk to be encoded in equal amount as
heterozygosity in each of 5 separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer are excluded
from consideration of genetic risk from pentagenic heterozygosity.
Colorectal cancer
Using the assumption E- 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by pentagenic heterozygosity. Values
of Go > 0.26 and 1.70 < GRR < 2.33 are found in Table 6. These values correspond to
values of 0.03 < q < 0.05 which includes the mean values of q of -0.03 for all non-
deleterious gene inactivating mutant fractions in human genes. If, for instance, were
recalculations for CRC to find GRR > 2.3, then this mode of simple Mendelian
inheritance would appear to be excluded.
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Hypothesis about multigenic heterozygous risk derived from this exercise
Once, however, one finds that risk as multigenic heterozygosity (m= 5, 6, 7) is in accord
with values of q estimated for all human genes carrying nondeleterious gene-inactivating,
one, in the words given to Hercule Poirot, "is given furiously to think". These findings
offer a fairly simple hypothesis bringing together some disparate points of CRC
epidemiology, physiology and familial risk. Could risk for late-onset CRC be inherited as
heterozygosity for any of 5-7 proto-oncogenes? No oncogenes for which activation is
required for neoplastic transformation have been found in all tumor cells in human
tumors. This conclusion stands despite the presence of sometimes large tumor sectors
"activated" for RAS and other murine and avian oncogenes. Could there be a set of
conditions of heterozygosity such A +/, B+ -, C+-, D+-, E+-, F'- in which heterozygosity
for any of these genes would confer risk of tumor promotion by alteration of the active
allele in a preneoplastic stem cell? Homozygous and nullizygous persons for genes A-F
would not be at risk as two rare events would be required for activation of one gene copy
and alteration of the other (homozygotes) while re-activation and then specific oncogenic
alteration of an inactivated gene copy (nullizygotes) would be at rates below any
reasonable expectation Such a scenario is in accord with estimates of rates of promotion
by single mutations in colorectal cancer in U.S. European American males (Herrero-
Jimenez, Tomita-Mitchell et al. 2000) and is worth considering further.
Multigenic nullizygous risk (m=2, each gene contributing equal risk)
[Figures 14.1-14.4 and Table 7]
All common late-onset cancers
It is clear from inspection of Table 7 that for risk of a common late onset cancer to be
inherited as a bigenic nullizygous condition, values of GRR must be less than 3.0 if the
fraction of the population at risk is greater than 0.076. Pancreatic cancer, the fifth most
deadly cancer form in the U.S. and for which mortality estimates are essentially identical
with incidence has an mLR for males of 0.08-0.09. But mLR for leukemia and other
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cancers appear to be lower than 0.04. Assuming pro tempore that environmental risks
now reach nearly all persons, values of GRR for pancreatic cancer would have to lie
between 2.8 and 2.9 were risk to be encoded in equal amount as nullizygosity in each of
two separate genes. As the Hemminki group has reported few estimates of GRR for late-
onset cancers higher than 3.0, but has reported a general absence of spousal risk, it
appears that risk the less common forms of cancer are excluded from consideration of
genetic risk from bigenic nullizygosity.
Colorectal cancer
Using the assumption E--1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by bigenic nullizygosity. Values of Go
> 0.26 and 1.72 < GRR < 1.77 are found in Table 7. These values correspond to values of
0.37 < q < 0.39 which is well above the 99% u.c.l. (0.22) calculated for the values of q
for all non-deleterious gene inactivating mutant fractions in human genes. If, for
instance, recalculations for CRC to find GRR > 1.8, then this bigenic mode of simple
Mendelian inheritance would appear to be excluded.
Multigenic nullizygous risk (m=3, each gene contributing equal risk)
[Figures 15.1-15.4 and Table 8]
All common late-onset cancers
It is clear from inspection of Table 8 that for risk of a common late onset cancer to be
inherited as a trigenic nullizygous condition, values of GRR must be less than 3.0 if the
fraction of the population at risk is greater than 0. 06. Pancreatic cancer, the fifth most
deadly cancer form in the U.S. and for which mortality estimates are essentially identical
with incidence has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 2.5 and 2.6 were risk to be encoded in equal amount as
nullizygosity in each of three separate genes. As the Hemminki group has reported few
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estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears the less common forms of cancer are excluded from
consideration of genetic risk from trigenic nullizygosity.
Colorectal cancer
Using the assumption E~ 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk cannot be conferred by trigenic nullizygosity. Values
of Go > 0.26 and GRR > 1.7 are not found in Table 8. If, for instance, were recalculations
for CRC to find GRR > 2.3 then this mode of simple Mendelian inheritance would
appear to be excluded with greater statistical assurance.
Multigenic nullizygous risk (m=4, each gene contributing equal risk)
[Figures 16.1-16.4 and Table 9]
All common late-onset cancers
It is clear from inspection of Table 9 that for risk of a common late onset cancer to be
inherited as a tetragenic nullizygous condition, values of GRR must be less than 3.0 if the
fraction of the population at risk is greater than 0.047. Pancreatic cancer, the fifth most
deadly cancer form in the U.S. and for which mortality estimates are essentially identical
with incidence has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 2.34 and 2.44 were risk to be encoded in equal amount as
heterozygosity in each of four separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer should be
included when considering genetic risk from tetragenic nullizygosity.
Colorectal cancer
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Using the assumption E- 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by tetragenic heterozygosity. Values of
Go > 0.26 and GRR > 1.7 are not found in Table 9. This mode, tetragenic nullizygous
risk, of simple Mendelian inheritance would appear to be excluded.
Multigenic nullizygous risk (m = 5, each gene contributing equal risk)
[Figures 17.1-17.4 and Table 10]
All common late-onset cancers
It is clear from inspection of Table 10 that for risk of a common late-onset cancer to be
inherited as a pentagenic nullizygous condition, values of GRR must be less than 3.0, if
the fraction of the population at genetic risk is greater than 0.04. Several forms of cancer,
such as leukemia, CNS cancers, and lymphoma, may meet this criterion for minimum
lifetime risk, mLR, which we use an estimate of the minimum value of Go. Pancreatic
cancer, the fifth most deadly cancer form in the U.S. and for which mortality estimates
are essentially identical with incidence has an mLR for males of only 0.08-0.09.
Assuming pro tempore that environmental risks now reach nearly all persons, values of
GRR for pancreatic cancer would have to lie between 2.2 and 2.3 were risk to be encoded
in equal amount as nullizygosity for each of 5 separate genes. As the Hemminki group
has reported few estimates of GRR for late-onset cancers higher than 3.0, but has reported
a general absence of spousal risk, it appears that risk from pentagenic nullizygosity
should be included when considering genetic risk for the less common forms of cancer.
Colorectal cancer
Using the assumption E-1I, the observation Go > 0.26 and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it does not appear to be possible that CRC risk can be conferred by pentagenic
nullizygosity. No values of Go > 0.26 and GRR > 1.70 are found in Table 10. This mode
of simple Mendelian inheritance would appear to be excluded.
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Polygenic heterozygous risk (n = 2, each gene contributing equal risk)
[Figures 18.1-18.4, Table I 1]
All common late-onset cancers
It is clear from inspection of Table 11 that for risk of a common late onset cancer to be
inherited as a polygenic (n=2) heterozygous condition, values of GRR must be less than
3.0 if the fraction of the population at risk is greater than 0.083. Cancers of the skin,
prostate, colorectum, breast, and lung (among cigarette smokers), meet this criterion for
minimum lifetime risk, mLR, which we use an estimate of the minimum value of Go.
Pancreatic cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR for pancreatic cancer
would have to lie between 2.8 and 3.0 were risk to be encoded in equal amount as
heterozygosity in each of two separate genes. As the Hemminki group has reported few
estimates of GRR for late-onset cancers higher than 3.0, but has reported a general
absence of spousal risk, it appears that risk the less common forms of cancer are excluded
from consideration of genetic risk from polygenic (n=2) heterozygosity.
Colorectal cancer
Using the assumption E- 1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki
group, it does not appear that CRC risk can be conferred by polygenic (n=2)
heterozygosity. No values of Go > 0.26 and GRR > 1.7 are found in Table I 1. This mode
of simple Mendelian inheritance would appear to be excluded as the basis of genetic risk
for CRC. It can be seen by inspection that all values of polygenic (n>2) nullizygosity are
similarly excluded for CRC and the several other most common forms of cancer.
Polygenic homozygous risk (n = 2-25, each gene contributing equal risk)
[Figures 19.1-19.4, Table 12] (N.B. values are for (l-q) = p in this table)
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All common late-onset cancers
It is clear from inspection of Table 12 that for risk of a common late onset cancer to be
inherited as a polygenic (n>2) homozygous condition, values of GRR must be less than
3.0 if the fraction of the population at risk is greater than 0.11. Cancers of the skin,
prostate, colorectum, breast, and lung (among cigarette smokers), meet this criterion for
minimum lifetime risk, mLR, which we use an estimate of the minimum value of Go.
Pancreatic cancer has an mLR for males of only 0.08-0.09. Assuming pro tempore that
environmental risks now reach nearly all persons, values of GRR < 3.0 do not exist for
polygenic (n>2) homozygosity for each of two to five separate genes for pancreatic
cancer. It appears that risk the less common forms of cancer, including pancreatic cancer,
are excluded from consideration of genetic risk from polygenic (n>2) homozygosity.
Colorectal cancer
Using the assumption E-1, the observation Go > 0.26, and a strictly preliminary range of
estimates of GRR for male CRC risk of 1.7 < GRR < 2.5 reported by the Hemminki group
it appears possible that CRC risk can be conferred by polygenic (n>2) homozygosity.
Values of Go > 0.26 and 1.7 < GRR < 1.96 are found in Table 12. This mode of simple
Mendelian inheritance would appear to be worthy of further consideration as the basis of
genetic risk for CRC.
These observations are summarized in Table 15 as calculated values of Go and GRR.
Monogenic risk of CRC
Using CRC as an example with Go> 0.26 and 1.5 < GRR < 3.0, a key conclusion is
reached: both monogenic heterozygous and nullizygous conditions of risk are included in
the set of possible modes of CRC risk inheritance. Were we, however, to use the
estimate, Go-0.35, derived from the relatively small set of proctoscopic studies reported
by Atkin (1993), monogenic nullizygous risk but not monogenic heterozygous risk is still
included for values of GRR between 1.5 and 1.7. Monogenic risks require values of q
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considerably above the 99% u.c.l. of 0.22 estimated for genes carrying gene-inactivating
non-deleterious mutations. Calculating the value of FRR(t) for father to son and mother to
daughter transmission of CRC risk for the age-intervals 50-54,...,70-74, should provide
ten separate estimates of GRR for CRC and permit some refinement of the rang we are
obliged to use herein. For example, if GRR for CRC is found to exceed 2.0, all forms of
monogenic risk will be seen to be excluded.
Multigenic risk of CRC
Using CRC as an example with Go> 0.26 and 1.5 < GRR < 3.0, it is clear that multigenic
heterozygosity is not excluded for a range 2.5 > GRR > 1.5 while multigenic nullizygous
risks are not excluded within a more narrow range - 1.7 > GRR > 1.5. Were the estimate
of CRC Go = 0.35 applied only more narrow ranges of GRR near 1.5 would continue to
include these possibilities. Recalculation of GRR as outlined above is clearly the next
crucial step on this scientific path. Note that if CRC GRR were found to be >2.0 the only
mode of Mendelian risk inheritance not excluded would be any of several levels of
multigenic heterozygosity.
Polygenic risk of CRC
Using CRC as an example with Go> 0.26 and GRR < 3.0, it appears that these modes are
generally excludable on the basis of the estimated minimum of Go and GRR alone. This
exclusion is, however, limited to the unlikely combination of genes carrying high values
of q. A useful follow-up in this regard would be to apply the general equations for
polygenicity in which values of q range broadly.
The calculations summarized in Table 16 offer food for additional thought. Using
Morgenthaler and Thilly's estimation of a mean mutant fraction of 0.03 for gene
inaxctivating mutations in genes that carry such non-deleterious alleles and their estimate
of a 99% u.c.1 of 0.22 we may apply that range to the values of Table 14. Note that high
values of q cannot be excluded, because a high value may occur once by chance and a
few such values might conceivably account for the values of Go for the most common
late-onset forms of cancer: skin, prostate, colorectal and breast. Multigenic or polygenic
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modes with multiple mutations each with high inherited mutant fractions may reasonably
be considered unlikely. But a model of multigenicity with genes carrying different mutant
fractions with the most frequent accounting for 1/3 to 2/3 of the total risk can be created
using the general equations derived herein and this possibility is worth pursuing. When
the multigenic or polygenic models show average values of q approaching the expected
mean of q = 0.03, special attention is due, as the expected mean of several genes drawn
by chance is 0.03.
The most important conclusion of this thesis is that it is possible to build a logical
quantitative structure to evaluate the probability that risk for a particular form of cancer is
transmitted by any of a series of simple Mendelian modes.
This process began with the use of lifetime incidence and mortality data to estimate the
minimum value of Go, as in Figures 5 and 6 for colorectal cancers. In this we applied the
reasoning developed in Herrero-Jimenez et al. (2000).
The second step, prescribed by our arguments, was taken to estimate the genetic relative
risk, GRR, by determining specific values of familial risk FRR in the age intervals 50-54
up to 70-74 for father-to-son and mother-to-daughter risk transmission. This work
provides a valuable redefinition of GRR, not heretofore developed, that should chart a
path for these calculations for all common cancers recorded in the Swedish Family
Cancer Database, organized by Prof. K. Hemminki.
The third step was to use the graphs and tables provided to discover if the values of Go
and GRR are excluded for each form of simple Mendelian inheritance posited. In these,
we extend the work of Li and Sacks (1954) by creating formule for GRR in the cases of
multigenic and polygenic risks.
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The application of this method to colorectal cancer in parent-to-child transmission in
Sweden indicates the important conclusion that monogenic forms of transmission are not
excluded by existing data but that recalculation of GRR (in progress) may in fact do so.
Application of this general method should be of immediate use to those who are planning
pan-genomic searches for genes that confer risk to common diseases such as cancers.
A major caveat must be stressed. If cardiovascular disease(s) share common determinants
of genetic risk with any other common disease such as CRC, estimates of Go derived
from lifetime incidence or mortality data will be gross underestimates. Such estimates
would need to be increased via a model in which persons at risk of the disease observed
competed with cardiovascular disease in each age interval. Creation of such a quantitative
model would prove useful in setting bounds on estimates of gene frequencies. Herein, we
assumed no interaction of cardiovascular risk, but future research may uncover links,
heretofore not discovered.
In this effort, we have tried to contribute to the development of a novel logical means to
analyze the genetics of common diseases such as cancers in the human population. In
concluding our part in this effort, we are confident that we have made original and
apparently important progress. We hope that will serve to guide others and stimulate
them to press on to more precise estimates of key parameters, and investigate more
carefully the possibility of shared genetic risks among cancers and other common
diseases.
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TABLE 14: SIR (Standardized Incidence Ratios) for offspring with parental history
Adaptation with permission (Hemminki, Rawal et al. 2004)
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Site SIR
Thyroid 7.13
Testicular 4.58
Esophageal 3.82
Ovarian 2.91
Endometrial 2.74
Prostate 2.42
Skin (SCC) 2.39
Multiple Myeloma 2.33
Endocrine 2.23
CRC 2.04
Cervix 1.95
Lung 1.90
Breast 1.80
Non-Hodgkin's 1.76
Bladder 1.73
Kidney 1.67
Nervous System 1.63
Leukemia 1.53
Pancreas 1.53
TABLE 15: Values of Go corresponding to values of GRR of 3.0, 2.5, 2.0, and 1.5
mono.het
mono.nul
multi.het.2
multi.het.3
multi.het.4
multi.het.5
multi.nul.2
multi.nul.3
multi.nul.4
multi.nul.5
poly.het.2
poly.hom
GRR = 3.0
0.1667
0.1111
0.1827
0.1883
0.1912
0.1929
0.0760
0.0580
0.0470
0.0395
0.0833
0.1111
GRR = 2.5
0.2
0.16
0.2238
0.2323
0.2367
0.2393
0.1157
0.0912
0.0754
0.0643
0.1
0.16
GRR = 2.0
0.25
0.25
0.2892
0.3036
0.3109
0.3154
0.1955
0.1617
0.1383
0.1209
0.125
0.25
GRR = 1.5
0.3333
0.4444
0.4108
0.4403
0.4553
0.4644
0.3891
0.3483
0.3165
0.2906
0.1667
0.4444
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TABLE 16: Values of q corresponding to values of GRR of 3.0, 2.5, 2.0, and 1.5
mono.het
mono.nul
multi.het.2
multi.het.3
multi.het.4
multi.het.5
multi.nul.2
multi.nul.3
multi.nul.4
multi.nul.5
poly.het.2
poly.hom.2
poly.hom.3
poly.hom.4
poly.hom.5
poly.hom.10
poly.hom.15
poly.hom.20
poly.hom.25
GRR = 2.5
0.09175
0.33333
0.05052
0.03480
0.02654
0.02144
0.19683
0.14042
0.10933
0.08958
0.17494
0.42265
0.30664
0.24016
0.19726
0.10404
0.07062
0.05345
0.04299
GRR = 2.0
0.11270
0.4
0.06352
0.04412
0.03379
0.02737
0.24420
0.17708
0.13927
0.11490
0.19687
0.36754
0.26319
0.20473
0.16745
0.08756
0.05926
0.04478
0.03599
GRR = 1.5
0.14645
0.5
0.08583
0.06046
0.04662
0.03793
0.32104
0.23893
0.19109
0.15954
0.22940
0.29289
0.20630
0.15910
0.12945
0.06697
0.04516
0.03406
0.02735
GRR = 3.0
0.21132
0.66667
0.13422
0.09743
0.07628
0.06261
0.46735
0.36471
0.30123
0.25762
0.28582
0.18350
0.12642
0.09640
0.07789
0.03974
0.02667
0.02007
0.01609
148
REFERENCES
Armitage, P. and R. Doll (1957). "A two-stage theory of carcinogenesis in relation to the
age distribution of human cancer." Br J Cancer 11(2): 161-9.
Atkin, W., P. Rogers, et al. (2004). "Wide variation in adenoma detection rates at
screening flexible sigmoidoscopy." Gastroenterology 126(5): 1247-56.
Beckman, R. A. and L. A. Loeb (2006). "Efficiency of carcinogenesis with and without a
mutator mutation." Proc Natl Acad Sci U S A 103(38): 14140-5.
Cascorbi, I. (2003). "Pharmacogenetics of cytochrome p4502D6: genetic background and
clinical implication." Eur J Clin Invest 33 Suppl 2: 17-22.
Czene, K., P. Lichtenstein, et al. (2002). "Environmental and heritable causes of cancer
among 9.6 million individuals in the Swedish Family-Cancer Database." Int J
Cancer 99(2): 260-6.
Frank, S. A. (2004). "Age-specific acceleration of cancer." Curr Biol 14(3): 242-6.
Goldgar, D. E., D. F. Easton, et al. (1994). "Systematic population-based assessment of
cancer risk in first-degree relatives of cancer probands." J Natl Cancer Inst
86(21): 1600-8.
Gostjeva, E. V. and W. G. Thilly (2005). "Stem cell stages and the origins of colon
cancer: a multidisciplinary perspective." Stem Cell Rev 1(3): 243-51.
Gruber, S. B., N. A. Ellis, et al. (2002). "BLM heterozygosity and the risk of colorectal
cancer." Science 297(5589): 2013.
Hageman, (G. S., D. H. Anderson, et al. (2005). "A common haplotype in the complement
regulatory gene factor H (HF1/CFH) predisposes individuals to age-related
macular degeneration." Proc Natl Acad Sci U S A 102(20): 7227-32.
Hemminki, K. and B. Chen (2004). "Familial association of colorectal adenocarcinoma
with cancers at other sites." Eur J Cancer 40(16): 2480-7.
Hemminki, K. and B. Chen (2004). "Familial association of leukemia with colorectal
cancer." Leuk Res 28(10): 1113-5.
Hemminki, K. and B. Chen (2004). "Familial risk for colon and rectal cancers." Int J
Cancer 111(5): 809-10.
Hemminki, K. and B. Chen (2004). "Familial risk for colorectal cancers are mainly due to
heritable causes." Cancer Epidemiol Biomarkers Prey 13(7): 1253-6.
Hemminki, K., C. Dong, et al. (2001). "Cancer risks to spouses and offspring in the
Family-Cancer Database." Genet Epidemiol 20(2): 247-57.
149
Hemminki, K., C. Granstrom, et al. (2005). "The Swedish Family-Cancer Database:
Update, Application to Colorectal Cancer and Clinical Relevance." Hereditary
Cancer in Clinical Practice 3(1): 7-18.
Hemminki, K. and Y. Jiang (2002). "Cancer risks among long-standing spouses." Br J
Cancer 86(11): 1737-40.
Hemminki, K. and Y. Jiang (2002). "Familial and second gastric carcinomas: a
nationwide epidemiologic study from Sweden." Cancer 94(4): 1157-65.
Hemminki, K., X. Li, et al. (2001). "The nation-wide Swedish family-cancer database--
updated structure and familial rates." Acta Oncol 40(6): 772-7.
Hemminki, K., R. Rawal, et al. (2004). "Genetic epidemiology of cancer: from families
to heritable genes." Int J Cancer 111(6): 944-50.
Hemminki, K., P. Vaittinen, et al. (1999). "Endometrial cancer in the family-cancer
database." Cancer Epidemiol Biomarkers Prey 8(11): 1005-10.
Herrero-Jimenez, P., G. Thilly, et al. (1998). "Mutation, cell kinetics, and subpopulations
at risk for colon cancer in the United States." Mutat Res 400(1-2): 553-78.
Herrero-Jirnenez, P., A. Tomita-Mitchell, et al. (2000). "Population risk and
physiological rate parameters for colon cancer. The union of an explicit model for
carcinogenesis with the public health records of the United States." Mutat Res
447(1): 73-116.
Kimura, M. and J. F. Crow (1964). "The Number of Alleles That Can Be Maintained in a
Finite Population." Genetics 49: 725-38.
Lander, E. S. and D. Botstein (1989). "Mapping mendelian factors underlying
quantitative traits using RFLP linkage maps." Genetics 121(1): 185-99.
Lander, E. S. and N. J. Schork (1994). "Genetic dissection of complex traits." Science
265(5181): 2037-48.
Li, C. C. and L. Sacks (1954). "The Derivation of Joint Distribution and Correlation
between Relatives by the Use of Stochastic Matrices." Biometrics 10(3): 347-360.
Lichtenstein, P., N. V. Holm, et al. (2000). "Environmental and heritable factors in the
causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and
Finland." N Engl J Med 343(2): 78-85.
Luebeck, E. G. and S. H. Moolgavkar (2002). "Multistage carcinogenesis and the
incidence of colorectal cancer." Proc Natl Acad Sci US A 99(23): 15095-100.
McDougall, I., F. H. Brown, et al. (2005). "Stratigraphic placement and age of modern
humans from Kibish, Ethiopia." Nature 433(7027): 733-6.
150
Meijers-Heijboer, H., J. Wijnen, et al. (2003). "The CHEK2 11 00delC mutation identifies
families with a hereditary breast and colorectal cancer phenotype." Am J Hum
Genet 72(5): 1308-14.
Michor, F., Y. Iwasa, et al. (2004). "Dynamics of cancer progression." Nat Rev Cancer
4(3): 197-205.
Morgenthaler, S. and W. G. Thilly (2006). "A strategy to discover genes that carry multi-
allellic or mono-allelic risk for common diseases: A cohort allelic sums test
(CAST)." Mutat Res.
Muniappan, B. P. and W. G. Thilly (2002). "The DNA polymerase beta replication error
spectrum in the adenomatous polyposis coli gene contains human colon tumor
mutational hotspots." Cancer Res 62(11): 3271-5.
Rees, J. L. (2000). "The melanocortin 1 receptor (MC1 R): more than just red hair."
Pigment Cell Res 13(3): 135-40.
Rees, J. L. (2004). "The genetics of sun sensitivity in humans." Am J Hum Genet 75(5):
739-51.
Sankaranarayanan, K. and R. Chakraborty (2000). "Ionizing radiation and genetic risks.
XI. The doubling dose estimates from the mid-1950s to the present and the
conceptual change to the use of human data on spontaneous mutation rates and
mouse data on induced mutation rates for doubling dose calculations." Mutat Res
453(2): 107-27.
Stein, W. D. (1991). "Analysis of cancer incidence data on the basis of multistage and
clonal growth models." Adv Cancer Res 56: 161-213.
Stein, W. D. and A. D. Stein (1990). "Testing and characterizing the two-stage model of
carcinogenesis for a wide range of human cancers." J Theor Biol 145(1): 95-122.
Strange, R. C. and A. A. Fryer (1999). "The glutathione S-transferases: influence of
polymorphism on cancer susceptibility." IARC Sci Publ(148): 231-49.
Thilly, W. G. (2003). "Have environmental mutagens caused oncomutations in people?"
Nat Genet 34(3): 255-9.
Tomita-Mitchell, A., B. P. Muniappan, et al. (1998). "Single nucleotide polymorphism
spectra in newborns and centenarians: identification of genes coding for risk of
mortal disease." Gene 223(1-2): 381-91.
Zheng, W., K. Khrapko, et al. (2006). "Origins of human mitochondrial point mutations
as DNA polymerase gamma-mediated errors." Mutat Res 599(1-2): 11-20.
151
